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Abstract
Griffin Fountain
COMPUTATIONAL STUDY OF DRUG INTERACTIONS OF RECEPTORS,
SPECIFICALLY GLYCOPROTEIN D HUMAN HERPES VIRUS 1 AND DOPAMINE
D4 RECEPTOR
2020-2021
Chun Wu, Ph. D.
Masters of Science in Pharmaceutical Science
This thesis introduces computer aided drug design methods in Chapter 1 and
discuss their applications on two receptors in Chapters 2 and 3: Glycoprtein D (gD) of
Herpes Simplex Virus 1 (HSV-1) and Dopamine Receptor D4 (DRD4). The Herpes
Simplex Virus is a human pathogen that develops unpleasant cold sores around the body,
most commonly around the mouth or genitals area. Currently there is no cure or vaccine
that can eliminate this virus. Glycoprotein D (gD) is a viral ligand for host cell receptors
such as nectin -1. This interaction mediates the entry of HSV-1. In chapter 2, we used
virtual screening to identify top 20 potential compounds from a Zinc library with over 17
million entries targeting gD. Out of the 20 compounds, two have been shown to
moderately inhibit the gD-receptor interactions and HSV-1 infection by our experimental
collaborator. Therefore, these two compounds are good lead compounds for further drug
development. The Dopamine Receptor is a large class of G-couple Protein Receptors
(GPCR’s) that have been linked to multiple psychological mental disorders including
Parkinson’s disease and schizophrenia. Dopamine 4 Receptor (D4R) belongs to a
subfamily of Dopamine receptors known as D2-like receptors. The D4R is a therapeutic
target due to its involvement in cognitive behavior and unknown biological pathway. In
chapter 3, we investigate the molecular interactions of a set of novel selective compounds
to D4R over D2-like receptors (D2R and D3R) using molecular dynamics simulations.
v
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Chapter 1
Intro to Computational Drug Design
1.1 Background
The process of bringing a new drug to market is a costly, time-consuming, and
risky process. The typical drug discovery and design cycle takes about 10 – 15 years to
hit the shelves, with an approximate cost ranging from $800 million USD to $1.5 billion
USD. [1] Advancements in combinatorial chemistry and high-throughput screening
technologies helped aid in the advancement of the drug discovery process, by screening
huge libraries of molecules in a short time. [2] Despite the increase in investment of new
drug development, their still shows very little improvement in output for successfully
launched molecules into the market over the last several years.[3] Therefore, various
approaches have been brought forward to reduce the research cycle, are more cost
efficient, and minimize failure rate. Computer-Aided Drug Design (CADD) brings forth
new techniques to tackle these issues and to closer to our goal.
CADD is widely used and offers tools and sources for storage, large data-sets,
analysis, manipulation of data, and modeling of compounds. By adopting the use of
computational methods, designing potential drug candidates can be completed more
rapidly and at a lower cost.[4] A variety of CADD tools have been developed to assist
with drug discovery; such identification of new lead compounds, identify biomolecular
targets of therapeutic interest, pharmacokinetic and pharmacodynamics properties. [5]
CADD has been classified into two different groups: structure-based and ligand-based
(Figure 1). The structure based CADD relies on the knowledge of the three-dimensional
(3D) structure of drug targets through methods such as X-ray crystallography, NMR,
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3DEM, and XFEL. So that the interactions of small molecules with drug targets can be
modelled and analyzed.

Figure 1
Two Categories of CADD Methods
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The Protein Data Bank (PDB) is a large archive of experimentally determined 3D
structures, allowing macromolecular structure data freely available without restrictions on
use. PDB was established in 1971 at Brookhaven National Laboratory and Cambridge
Crystallographic Data, and since then, hundreds of thousands of proteins, DNA, RNA
and complexes, have been generated to aid in drug discovery and development (Figure
2). Though a large library of proteins is accessible, there are times when the 3D structure
2

or binding site is not accurately known. Thus, ligand-based CADD techniques are applied
to resolve this issue by studying experimentally active compounds that bind to the
biological target of interest. Using techniques like 3D quantitative structure-activity
relationships (3D QSAR), absorption, distribution, metabolism, excretion and toxicity
(ADMET) predictions and pharmacophore modeling are widely used tools in ligandbased drug design. Quantitative structure-activity relationship (QSAR) can also be
applied for its computing properties. It is used to develop a relation between the chemical
structure properties to its biological activity.

Figure 2

Number of
Entries

Overall Growth of Released Structure per Year to 2020[6]

Year
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With all these tools at our disposal, we can identify target protein and incorporate
ligand into the appropriate active site to estimate binding energy based on molecular
dynamic simulation. One major finding that incorporated computational methods in their
research lead to the identification of new Ca2+ channel blockers by using virtual
screening methods.[7] Thus showing the power and ability that CADD possess.
Introducing CADD into the drug discovery system has significantly changed the
strategy and pipeline of drug discovery (Figure 3). Making it a promising tool for future
progress in drug discovery and development. However, there are still limitations that
exist despite the advancement in technology. For example, molecular dynamics
simulation time is limited to only hundreds of nanoseconds or a few microseconds
depending on the size of the system. Larger and more complex structural proteins require
will fold many times over a longer range of milliseconds to seconds, leading to
insufficient analysis for these structures. The quality of a molecular force field needs to
be improved, because it is very crucial in modeling the structure and dynamic properties
of a molecular system. A force field is used to estimate the forces of atoms within a
molecule. The force field must be set to optimal parameters which is a key component to
computational research in generating accurate structural results. To address these specific
problems, more advanced hardware, simulation methods, and optimization techniques
have been brought forth.
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Figure 3
Multiple Computational Drug Discovery Techniques and Approaches Have
Been Applied in Various Stages of the Drug Discovery and Development
Pipeline

The focus of this work is to apply computational tools and techniques to aid in the
development of new pharmaceutical candidates. Before going into further detail, I will
discuss a brief overview of the theory behind these methods.
1.2 Methodology
1.2.1 Virtual High Throughput Screening
With numerous amounts of ligand to be tested and analyzed, High Throughput
Screening (HTS) has been used to achieve rapid identification of lead compounds.
However, due to HTS huge cost and time consumption, a cheaper computational method
had to be employed to analyze the large amount of compounds that are available. Virtual
High Throughput Screening (vHTS) is used as a cheaper and effective computational
method to analyze a library of compounds to predict binding affinity at the target
receptor. vHTS can be carried out using receptor-based or ligand-based screening
methods. Receptor-based screening methods involve a known 3D structure of the target
5

receptor to search for potential candidates that can successfully bind and modulate the
target receptor function. From library of compounds docking in the receptor binding site,
the top compounds are selected based on their binding score for further analysis in vitro
validation.
When the 3D structure of the target receptor is unavailable, ligand-based methods
are used from the information provided from known inhibitors or other ligands that
possess drug like characteristics. Compounds that share similar structures as the known
inhibitors are identified from online databases are identified to continue with the
screening process to filter out a smaller group of compounds.
1.2.2 Homology Modeling
There will be times in which the researcher doesn’t have the necessary crystal
structure for the target protein. The next option is build a homology model the active site.
A homology model gives a model of the entire protein. Homology modeling is used when
the researcher is trying to determine the structure of the primary sequence without
waiting on crystallography results. A search is carried out to determine which proteins
structures are available that are nearly identical as the primary sequence. Homology
modeling is a multistep process (Figure 4), and often times requires iterating previous
steps to validate the model. The overall process of homology modeling involves putting
pieces together, optimizing the geometry, and analyzing to see if a reasonable structure
has been generated.
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Figure 4
Flow Chart of Homology Modeling Process
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1.2.2.1 Template Identification. The objective of template identification is to
find a known protein structure that has high sequence similarity to the model sequence. A
successful template should have a protein structure with high percentage of similarity and
identity. Similarity is the resemblance between the two structures while identity means
the amount of residue the match exactly between the two structures. Analyzing multiple
structures and comparing resolutions and is encouraged to obtain the best model.
1.2.2.2 Alignment Between Unknown and Template. Alignment is carried out
to see how well the unknown 3D structure sequence aligns with the template sequence.
7

Since the only information that is currently available to us is the sequence of the
unknown structure, this can be aligned with a known structure (template) that has a high
similarity to the unknown structure. Sequence alignment is typically accompanied by
using Basic Local Alignment Search Tool (BLAST) which uses rigorous algorithms to
compare primary biological sequences between the query sequence and all the sequences
in a database. The BLAST will generate a model of the predicted 3D structure of the
unknown that was aligned against the template.
1.2.2.3 Manual Adjustments. There are more ways to align unknown sequence
to the template to achieve a reasonable alignment. A common situation to see is the
template containing a few residues that are different/present from the unknown sequence.
Meaning, since some of the residues are different between the two or the unknown
sequence is missing residues compared to the template, adjustments must be made to
account for this by editing these errors. This is done by changing or adding the missing
residue to the unknown that is found in the template.
In rare cases, using a multiple sequence alignment is used to piece together a
homology model from different protein structures. This method is often lease favorable
because it produces the least favorable homology model. If a good template is not found,
or a piecewise method does not work, a threading algorithm may be used. This algorithm
tries multiple folding motifs and checks to see which one gives the best reasonable
structure to see which one gives the best end result.
1.2.2.4 Replace Template Side Chains with Model Side Chains. Often times
the template strand will not have identical side chain and will be replaced by the side
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chain of the model compound. The only difficult part of this step is optimizing the threedimensional part of the new side chain. The best way to fix this is to optimize the portion
of the new side chain that has been inserted. Later on, the whole structure will go through
optimization and validation. If the validation identifies that side chain position as
questionable, it may suggest going back and insert another side chain from a better
conformer.
1.2.2.5 Insertions and Deletions. Insertions and deletions are often found in the
loops of the structure. The loop of the structure is the most flexible portion of the
structure and is found in regions near the active site and areas that are affected by crystal
packing forces. Once the correct residues are placed, their positions must be optimized.
1.2.2.6 Model Optimization. The steps that were used to generate the structure
up to this point does not provide the optimal geometry. The backbone geometry of the
template and unknown will be similar but not identical. When the backbone of the
template is adjusted, that in turns makes it necessary to readjust the side chains and
rotamers as well. The issue here is to decide which optimization scheme is appropriate.
Techniques such as energy minimization and conformational search techniques can be
used, but each with their own limitations. Another way is to run a molecular dynamics
simulation to determine the best conformational pose. By adjusting the heat, the
simulation can explore the conformation space without unraveling the fold of the protein.
1.2.2.7 Model Validation. At this point, the homology model of fully
constructed, but the researcher should still take the necessary steps to look over and
determine if the steps carried out were done correctly. Besides comparing the structure
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with the crystal structure, there is no reliable way to validate the structure. Checking the
bond lengths, dihedral angles, torsion angles, and bond angles are some of the general
areas that should be inspected. Often times, if the structure has gone through a
minimization step, these factors would have been set to reasonable parameters. Using a
Ramachandran plot is a good visual representation to determine if the conformational
rotations are similar to the backbone of the folded protein. Programs like ProCheck,
ERRAT, ProSa, PROVE and Q-PACK are used commonly to see if the model is good or
bad.
1.2.2.8 Iteration. Each step of homology modeling can be carried out
successfully and there may still be an error that was overlooked during one of these steps.
However, the step that should be looked over is only necessary depending on the impact
it made. If the hydrophilic/hydrophobic are facing the wrong way, one could suggest that
the backbone itself is incorrect. To fix this issue, one may need to start over and use a
different template structure. If majority of the errors are in the loops, then one should reoptimize those specific regions. Another method is to optimize the whole structure to
achieve better results. Errors of the structure are estimated by this set of criteria:
Alignment, RMSD of Cα atoms calculations, Z-score, and scoring functions to
discriminate between good and bad models.
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1.2.3 Docking
Molecular docking is a structure-based drug design method that has been widely
used and applied in the drug discovery pipeline since the 1980s.[8] Since then, molecular
docking has become a key tool in the drug discovery process. It uses automated computer
algorithms to determine how well a compound will bind in the active site of the target
receptor. This includes using algorithms to determine the compounds orientation,
possible poses, conformational geometry, and scoring. Many docking algorithms try and
put the compound in many different poses and generates a score for each. This is where a
search algorithm is used to predict all possible orientations and conformations of the
protein docked with the ligand. Another docking algorithm that is used is Glide docking,
which is fast and accurate at predicting the correct binding modes. The aim of molecular
docking is to predict the most favorable pose of ligand within the active site of the
receptor using computational methods. Thus, enabling us to characterize the behavior of
the small molecule within the binding site of the target protein.
If the location of the ligand binding site is unknown, different methods can be
carried out to obtain this information. By using these methods, we can predict the most
likely binding location on the protein, and other possible binding locations that could be
present on the protein structure. There are numerous programs and online servers that
detect these binding sites or cavities that are unknown such as I-TASSER[9]. The
binding site detection method used to identify the binding location of a protein will be
discussed later in this paper.
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There are two basic steps for docking: initial prediction of ligand positioning in
binding site and application of scoring function to assess the strength of binding affinity.
During the docking process of the ligand, the protein is in a fixed position and the active
site does not undergo any significant conformational changes upon ligand binding.
However, applying more rigorous algorithms and computational power make it possible
to develop better understanding the ligand has on the protein target. In this paper, we will
discuss how we used three different types of docking simulation including SP Docking,
XP docking, and Induced-Fit docking.
1.2.3.1 Binding Site Detection with Known Protein Target. There are many
protein structures out there that already have a ligand in the active site of the target
protein. By using different biological techniques like X-ray crystallography and nuclear
magnetic resonance (NMR) methods, this information can be available to us to use and
manipulate as we please. However, due to the different classes of receptors that play
different biological roles, their structures can exist in multiple structure states. Some
receptors can alternate from one state to another without the presence of a ligand or
protein interacting with the target protein. To account for the possible states the protein
has, we must first understand the biological role that the protein plays.
Agonist and antagonist are two main classes of drugs that causes its biological
target receptor protein to change confirmation and biological response. An agonist can
bind and activate the receptor, producing a biological response. An antagonist can reduce
or inhibit the biological response by binding to the receptor and blocking other small
molecules to bind to binding site. In computational studies, it is crucial to understand
what state the receptor is in when analyzing the crystal structure. By understanding what
12

state the protein is in, either it be inactive or active, closed or open, occupied or
unoccupied, gives researchers useful information to identify the conformation of the
protein.
1.2.3.2 Binding Site Detection of Unknown Active Site. It is essential to identify
binding sites on the protein surface so that small molecules can bind and induce a
biological effect, as well as locating binding cavities that could disrupt interaction
between protein-protein interactions. Binding site detection is an important task in
successful drug discovery. Traditional approaches for binding site detection use search
algorithms, binding site by structural alignment (template)[10][11][12], energybased[13][14][15], geometry-based approaches[16][17][18], propensity-based[19][20], or
combination-based[21]. Figure 5, illustrates some possible binding sites that could be
detected and used for docking studies of small molecules. If more than one active site is
discovered, the region containing the highest score will be selected.
These traditional approaches rely on a two-step method, in which potential
pockets or cavities are first identified and then scored to determine which one is the
potential binding site. In this research, the Maestro Site-map[22] method was used to
determine different binding sites on the surface of the protein for ligand-protein
interaction. Site-map application is a fast and easy to use tool that provides researchers
with a visual aid to evaluate and exploit the characteristics of potential ligand binding
sites with a high degree of confidence. Making Site-Map a useful tool for identifying
potential binding sites, lead discovery application, characterizing binding sites, and leadoptimization.
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Figure 5
Possible Binding Sites in Receptor

Note. The silver molecule represents an ideal docking site, blue and red represent less
favorable docking sites in the receptor. Scores are generated to allow us to select the most
favorable docking site for research

1.2.3.3 SP and XP Docking. Schrodinger provides the necessary tools and
methods to accurately scoring and docking poses of ligand. Glide is a docking tool used
in Maestro Schrodinger, with Standard Precision (SP) and Extra Precision (XP) mode,
with the capability to dock large amounts of ligands with high accuracy. The Glide
algorithm approximates a systematic search of poses, positions, orientations, and
conformations of the ligand binding to the active site of the receptor using a series of
hierarchical filters. SP and XP docking mode use the same general docking algorithm,
but XP uses extensive algorithms to eliminate false positives and more rigorous
algorithms. The SP docking method is a very quick and easy computational method to
rank potential candidates based on their docking score. Due to its short time frame, it is

14

ideal method to use to rank a large group of ligands. However, due to its simple scoring
method, it will only generate a limited possible structural pose. XP docking scoring can
be a more reliable method for scoring function when docking multiple ligand.
1.2.4.1 Induced Fit/Flexible Docking. The conformational changes of residues
that occur around the active site is heavily influenced by bound ligand. Analyzing the
resolving protein-ligand requires a necessary amount of time. Schrodinger Induced-Fit
protocol help resolve this issue by using Glide and Prime to accurately predict the various
binding poses of the ligand and structural changes in the receptor. Unlike SP or XP
docking that use a rigid receptor to study ligand poses, IFD studies the conformation
changes and orientation of the binding site that is influenced from the various poses of
the bound ligand.
The aim of using IFD is to generate an accurate complex structure of a known
ligand that is known to have binding activity but is unable to dock to rigid structure of the
receptor. As well as using additional receptor conformations that were obtained from IFD
protocol to screen against true binding ligand that were scored poorly.
1.2.4 MD Simulation
Molecular Dynamics (MD) simulation is a key tool in the theoretical study of
biological systems to provide detailed information on the fluctuations and conformational
changes of micro- and macro molecules. Carrying out molecular simulation acts as a
bridge between the microscopic interaction and time scale of structures. With very little
limitation, such as computer budget, adjustments to the simulation to predict the accuracy
were made. Molecular dynamics is involved in the simulation of protein folding with
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small-molecules on an atomic level[23], investigating atomic positions and velocities of
these biological molecules and their complex (Figure 6). Molecular dynamics plays a
key role in drug discovery, including identifying potential allosteric binding sites,
enhancing traditional virtual-screening methodologies, and predicting binding free
energy. Using this method, microscopic systems can be investigated more thoroughly and
accurately which will open more doors to understanding the changes occurring in a real
biological experiment.

Figure 6
Molecular Dynamics Simulation Box With Receptor (Purple) and Crystal Ligand (Green)
With Lipid and Water Molecules Surrounding the Receptor and Ligand
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Classical molecular dynamics is based on Newton’s second law of motion, F=ma,
where F is force exerted on an object, m is its mass and a is its acceleration. It uses this
equation to study the physical movement of atoms and molecules in the system to
generate trajectories of n particles. Using this method, the Newton’s classical law of
motion can be derived in n particles:
2

⃗⃗
𝑑𝑣
𝑑 𝑟⃗
𝐹⃗𝑛 = m𝑛 𝑎⃗𝑛 = m𝑛 𝑑𝑡𝑛 = m𝑛 𝑑𝑡 2𝑛 Eq. 1

In Equation 1, Fn is the force being exerted on due to the interactions with other
atoms, mn is the mass of the atom, an is the acceleration, which is the first derivative of
𝑑2 𝑟⃗

⃗⃗
𝑑𝑣

velocity ( 𝑑𝑡𝑛 ), and acceleration is the second derivative of position ( 𝑑𝑡 2𝑛). This classical
mechanism can generate the atomic positions and velocity of the molecular dynamic
simulation, allowing the state of the system to be determined in anytime in the future or
past.
To observe the macroscopic information such as pressure, energy, heat capacities,
etc., from microscopic information, statistical mechanics is applied. Statistical methods is
the bridge to explore the macroscopic properties of a system through microscopic
simulation. Statistical mechanics provide rigorous algorithms to examine the mechanics
and energetics of conformational change. Through MD simulation, different macroscopic
properties are explored and averaged over all atoms in the system over time to obtain
thermodynamic properties.
At a microscopic level, a system containing N particles is characterized by
positions ri and momenta pi, to define the state of a system. A combination of positions
and coordinates can define any value, or state, constrained by thermodynamic parameters.
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All these possible states of a system are represented in a 6N dimensional space, or phase
space. A single point in a phase space is denoted as ΓN, to describe the state of the
system. A large set of points in a phase space satisfying the conditions of a particular
thermodynamic state is called an ensemble.
Quantum, ab initio, MD simulations uses mathematical equations that incorporate
the behavior of nuclear and electronic interactions between particles. Ab initio means
“from the beginning”, meaning that QM used for computational methods is based solely
on laws of nature. Quantum mechanics equations were formulated since the 1920s,
through work of Schrodinger, Heisenberg, Born, and many others. Though these
principles are applied to any system, they do not provide an exact quantitative result,
except for one electron systems. To overcome this obstacle, different schemes have been
applied.
Applying computational techniques makes it possible to use these algorithms and
mathematical equations with ease. Almost all ab initio quantum mechanics equations are
derived from the time-dependent Schrodinger equation:
̂ (𝑟⃗, 𝑡) = 𝑖ħ  (𝑟⃗, 𝑡)
𝐻
𝑡

Eq. 2

This equation applies to quantum systems, by describing the systems wave
̂ , represent the molecular Hamiltonian which is associated with kinetic
function, (psi). 𝐻
and potential energies of the quantum system, and ħ is Planck’s constant. Other equations
like Hartree-Fock[24], Born-Oppenheimer[25], Density Functional Theory[26] etc also
play a major role in quantum mechanics.
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1.2.5 Molecular Mechanics and Force Fields
Molecular Mechanics (MM) is a classical method that is used to predict the
energy of a molecule as a function of its conformation. MM uses the sum of the bonded
and unbounded terms (bonds, angles, torsion, dihedrals, and nonbounded pairs) to find its
minimum-energy geometry (Figure 7). Molecular Mechanics models an atom and bond
as spheres and springs, respectively. The mathematics of spring deformation is used to
describe the ability of bonds to stretch, twist and bend. The atoms interact with each other
by attraction or repulsion, which determines the non-bonded interaction energy. The
form of this mathematical expression for the energy coupled with the parameters in it
constitute a force field. The parameters within a force field are used to accurately
determine the potential energy between atoms.
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Figure 7
Molecular Mechanics Potential Energy Functions
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Note. The molecules are represented as spheres (atoms) connected by a line (bonds). The
bonded terms are the sum of bond, angle, torsion, and improper terms. The unbonded
terms are the sum of van der Waals and electrostatic interactions for atoms i and j. Force
constants kb, kθ, kφ kω, Lennard Jones parameter εij, Aij, Bij, and partial charges qi and qj
are all atom specific parameters that are inputs to the simulation

Molecular mechanics is fast, requires less computer power and is a more costeffective method than QM but still has some limitations worth noting. Molecular
Mechanics is restricted by what type of molecules it can solve depending on the forcefield. Even though it can calculate the geometries and energy of large molecule such as
proteins and nucleic acids, it still does not have the information about electrons or
electronic properties. [27]
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1.2.6 Binding Free Energy
In computational aided drug design and discovery, obtaining an optimal binding
score has often been the end goal. Over the years, a number of different approaches have
been brought forward to calculate binding free energies, each of with its own trade-offs
of computational cost versus accuracy. [28] Free energy is the key quantity to describe
the thermodynamics of biological systems. The binding free energy can be classified into
two categories: pathway and end-point methods. Computational binding methods like
MM/PBSA and MM/GBSA incorporate the end-point method since these methods
calculate the free energy between the bound and unbound states of two solvated
molecules.
1.2.6.1 MMPBSA (Molecular Mechanics/Poisson Boltzmann Surface Area) &
MM-GBSA (Molecular Mechanics/Generalized Born Surface Area). One method to
obtain binding energy is by applying the MMPBSA (Molecular Mechanics/Poisson
Botzmann Surface Area) method. This method is widely applied binding free energy
method of small molecule ligand bound to large biomolecules.[29] The PoissonBoltzmann equation is used to compute electrostatic contribution to free energy. The first
end point method to be used was developed by Kollman et al. in the late 90s. In equation
3, ΔGbind is estimated from the free energies of reactants and product,
ΔGbind = (GPL) – (GP) – (GL)

(3)

The free energy state of the complex (PL), ligand (L) or protein (P) that is estimated in
equation 3, is further broken down into different interaction and expresses as:
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ΔGbind = ΔH - TΔS ≈ ΔEMM + ΔGsol - TΔS

(4)

ΔEMM = ΔEinternal + ΔEele + ΔEvdW
ΔEinternal = ΔEbond + ΔEangle + ΔEtorsion
ΔGsol = ΔG(PB/GB) + ΔG(SASA)

(5)
(6)
(7)

In which

ΔEMM represents the gas-phase of the molecular mechanics energy, including
internal energies (bond, angle, torsion), electrostatic and van der Waals contribution.
ΔGsol represent the sum of solvation energy ΔG(PB/GB) (polar contribution) and ΔG(SASA)
(non-polar contribution). The polar contribution is solved using either the PB or GB
model, and the non-polar contribution is estimated using the solvent-accessible surface
area (SASA). From the equation listed above a three-dimensional structure of the ligand,
protein and complex can be predicted by using implicit solvation methods GBSA or
PBSA in Figure 8.

Figure 8
Free Energy of Ligand Binding (PDB: 6D49)

22

1.2.6.2 Validation of Results. With binding energies being generated through
computational means, incorporating biological results can help provide a better insight in
determining potential lead compounds. Though some biological methods are costly and
time consuming, having their binding energy and correlating to computational data, could
suggest the efficiency of computational tools.
1.3 Thesis Outline
Chapter 2 will discuss an application of virtual screening in finding lead
compounds for the treatment of Herpes Simplex Virus (HSV). HSV infects a majority of
the American population. With no vaccines or cures against the virus, it has been a
challenge to reduce the spread of this virus from person to person. As drug resistance for
the virus increases, new strategies are highly desirable. Viral glycoprotein D (gD) is a
viral ligand and binds to cellular receptors such as HVEM or nectin-1 to enter the host
cell. Structural analysis of gD alone or in complex with a receptor suggest that the gDreceptor interaction induces a conformational change of gD for its activation, eventually
leading the membrane fusion and the entry of HSV. The C – terminus of the ectodomain,
is displaced from the gD core allowing a small pocket to be exposed. This small
hydrophobic pocket is essential for stability of native gD and for nectin – 1 and HVEM
binding. It is an ideal target to develop a small-molecule inhibitor that blocks the
essential interaction between gD and the host cell surface receptor, ultimately
neutralizing the virus. Virtual screening was performed to predict potential hit
compounds based on their docking score followed by MM-GBSA binding score. The top
20 compounds were purchased by our experimental collaborator to test their ability to
disrupt the function of gD and inhibit infection. Among them, two compounds that shared

23

similar chemical structures reduced gD and nectin – 1 binding and inhibited viral
infection in cell culture, making them good lead compounds for further development.
Work mechanism of these two compounds were investigated by ligand-receptor
interaction diagram and pharmacophore modeling.
The dopamine receptor belongs to a superfamily of G-protein coupling receptors
(GPCRs). The dopamine receptor mediates different functions of the central nervous
system responsible for locomotion and cognition. In chapter 3, we will focus on the
Dopamine D4 receptor, a subtype belonging to the D2-like subfamily. The D4 receptor
has been linked to a variety of physiological disorders including Schizophrenia, ADHD,
and Parkinson’s. Based on A-412997, a classical D4R partial agonist, a set of 6
derivatives have been developed by our experimental collaborators to show significant
improvements in D4R binding selectivity over other D2-like receptors (D2R and D3R)
and interesting shifts in their ligand efficacy profiles. Currently there is no high
resolution structure of D2R, D3R and D4R in complex with these ligands and their
detailed interaction mechanism is unknown. The six compounds were docked to the
crystal structure of the D2R, D3R and D4R (6CM4, 3PBL and 5WIU respectively).
Molecular dynamics simulations were carried out to determine their binding profile. The
six compounds were separated into three groups based on their structural modifications
and biological activity. The detailed structure and dynamic information from the MD
simulations offers molecular insights to explain the structure-activity relationship in the
three groups, providing hints for further lead optimization.
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Chapter 2
Herpes Simplex Virus (HSV)

2.1 Sexually Transmitted Infections (STIs)
Sexually transmitted infections are a type of infection caused by different
bacteria, viruses, and parasites that are transmitted from one human to another through
sexual contact. Often times different STIs can be present or transmitted simultaneously
and increases the risk of contracting other types of STIs. There are eight pathogens that
pose the greatest risk of contracting STIs. Currently there are only four different types of
STIs that can be cured with antibiotics: syphilis, gonorrhea, chlamydia, and
trichomonas’s. However, other viral infections such as HIV, HPV, herpes, and hepatitis,
have no cure but their symptoms can be alleviated with treatment. In this present chapter,
we will be focusing on Herpes simplex virus, a sexually transmitted infections that is
present at various body sites, most commonly on the genitals or mouth region.
2.2 Background of Herpes Simplex Virus
The herpes simplex virus (HSV), is one of the most common types of sexually
transmitted infections, affecting about 60-95% of the adult population worldwide. [30]
The herpes simplex virus exists in two different antigenic types, HSV-1 and HSV-2, with
HSV-1 typically involved in oral mucosa and HSV-2 typically involved with genital
mucosa. Both belong to Herpesviridae family. Herpesviridae is a large family of DNA
viruses that is divided into three subfamilies: α (alpha), β (beta) and γ (gamma)
herpersviruses, based on their biological properties. Currently, eight different type of
herpesvirus are recognized to routinely infect only humans. HSV-1, HSV-2 and Variclla-

25

zoster virus (VZV) belong to the alphaherpesvirinae.[31] These alphaherpesviruses have
a short reproductive cycle and can establish a lifelong latency in their host.[32][33]
2.2.1 Pathogenesis
HSV-1 and HSV-2 is a primary or recurrent infection of mucous membranes.
Primary HSV infections are mainly symptomatic, longer duration of symptoms, and
increase in difficulty for treatment. While recurrent infections are generally less severe
and are shorter. The most commonly seen clinical manifestation for HSV-1 occurs above
the waist. With patients expressing symptoms around the oral-facial regions. HSV-2 are
dominant below the waist, affecting areas around the genitals, inner thigh, and in some
cases the rectum area.
The virus must come in contact with the mucosal surface or abraded skin for
infection to be initiated. After inoculation onto the skin or mucous membrane, an
incubation of four to six days will take place.
2.2.2 Life Cycle
The herpes simplex virus has generally nine steps in its life cycle: 1) Attachment
and entry into host cell, 2) Release of viral DNA, 3) Sequential transcription and
translation that yield; immediate-early (α), early (β) and late (γ) proteins, 4) DNA
replication, 5) DNA is package into preformed procapsids, 6) Maturation, 7) Budding and
release of mature nucleocapsids, 8) Further maturation, and 9) release of virons via
exocytosis (Figure 9).
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Figure 9
Life Cycle of Herpes Virus

Note. (1) Attachment and entry into host cell, (2) Release of viral DNA, (3) Sequential
transcription and translation that yield; immediate-early (α), early (β) and late (γ)
proteins, (4) DNA replication, (5) DNA is package into preformed procapsids, (6)
Maturation, (7) Budding and release of mature nucleocapsids, (8) Further maturation, and
(9) release of virons via exocytosis

2.2.3 Structure
The herpes virus comes from a large family of DNA viruses known as
Herpesviridae. They consist of four key components: glycoprotein-containing envelope,
double-stranded DNA core, a capsid and tegument.[34] The dsDNA genome is
approximately 152 kbp long and is enclosed by a icosapentahedral capsid which is
composed of capsomers; a subunit of capsid.[35] The capsid is 125 nm in diameter and
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approximately 15 nm thick. It is composed of 162 capsomers, of which are 12 pentons
and 150 hexons. The capsid is surrounded by viral matrix called the viral tegument which
is enclosed by a glycoprotein-bearing lipid bilayer envelope. The tegument layer can be
20-40 nm thick, depending on the virus species. The tegument layer is composed of
virus-encoded proteins that aid in transcription, viral replication and virulence, viral
assembly, and interaction with the host cell.
The herpes simplex virus contains multiple envelope proteins called
glycoproteins. HSV encodes a total of 12 glycoproteins, each with their own role in entry
and membrane fusion. [36]Glycoproteins gB, gD, and gH/gL play a critical role in HSV
entry and fusion, while gC enhances the efficiency of entry.[37]
2.2.4 Entry of HSV Into Host Cell
The herpes simplex virus is one of the few human viruses that require interaction
with cell adhesion molecules to enter neurons and epithelial cells. Glycoprotein D (gD),
a viral protein, plays an important role with the entry of HSV virus into the host cell.
Once gD binds to one of its cellular receptors, it will trigger a conformational change to
gD. This signals an assembly of a fusion complex required for viral entry (Figure 10).
[38] Glycoprotein D is a viral ligand for a few receptors like nectin -1, HVEM
(Herpeviruse entry mediator) and modified 3-O-sulfated-herparan sulfate (3-O-HS),
which assist in execution of endocytosis.[39][40][41] Preventing viral glycoproteins to
interact with cellular receptors, can aid in developing a pharmaceutical agent to inhibit
this interaction.
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Figure 10
Mechanism of HSV-1 Entry Into the Host Cell

Cell

The interaction of Glycoprotein D binding to one of the cellular receptors has
become an acceptable model that is required for viral entry. Once gD binds to one of its
cellular receptors, it will induce a change in gD’s conformation, a key step to trigging
fusion.[42] After gD goes through a conformational change, it will interact with gH/gL,
an important step that is required for fusion. gH/gL exist as a heterodimer, though their
role is not entirely clear, it is suggested that gH/gL may act as a bridge for gD and
gB.[43] Studies have shown that the gH/gL complex are intertwined in a particular
fashion, that they each require one another for proper folding.[44] gB is class III
fusogen, possessing multiple fusogenic domains.[45] Once the gH/gL complex is
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activated, a signal is passed from the heterodimer to gB. These four glycoproteins play a
critical role in the mediation and entry of the virus. Each possessing their own role in
assisting the virus to overcome the barrier and enter neurons and epithelial cells.
The virus is surrounded by a variety of Glycoproteins, each branching out of the
virus like spikes, ready to bind to cells and initiate endocytosis. These spikes interact with
biological markers to mediate HSV entry upon binding; like nectin-1 and HVEM
(Herpesvirus entry mediator). Nectin is identified as a cell adhesion molecules consisting
of four members; nectin-1 to nectin-4. Nectin-1 is a Calcium independent
immunoglobulin-like adhesion molecule that is involved in the formation of adherens
junctions in epithelial cells and fibrolasts. Nectin-1 is the main nectin that helps mediate
the HSV into the cell and binds to the Glcyoprotein. Herpesvirus entry mediator (HVEM)
assists in entry of HSV by interacting with a viral envelope protein. It plays a range of
roles in a variety of pathogens. Though there is a greater importance of nectin-1 for the
pathogenesis of HSV, HVEM plays in important role in ocular infection following ocular
HSV infection.[40] The main glycoprotein that binds to the cellular receptor is gD, and
once the viral ligand is binding to nectin-1 or HVEM, it will initiate the entry of HSV.
The crystal structure of gD contains a V-set immunoglobulin consisting of large
terminal N- and C- terminal extensions.[46] These large flaking terminals engage and
bind to HVEM and nectin-1. Once gD is in the presence of either HVEM or Nectin-1, the
C-terminal loop in gD should displace from its present location within gD. This
movement exposes a binding pocket in gD to bind to nectin-1. The relocation of the Cterminal and exposing of the binding pocket is a crucial step for triggering fusion.[47]
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Recent studies have found gD lacking the C-terminal loop, exhibits a much higher
affinity for nectin-1, suggesting that the loop plays a role in fusion of HSV.[47]
2.3 Treatment
2.3.1 Current Treatment
Currently, there are no drug on the market that can cure herpes, only a few
antiviral medications that are used today to reduce the symptoms, see Table 1. Antiviral
drugs such as valacyclovir, acyclovir and famciclovir function as against HSV infection,
which inhibit DNA polymerase and slow down infection but does not cure the infection
completely.[48] With inappropriate prescribing and uncontrolled use of antiviral drugs,
can lead to drug resistance to the viral infection. Thus creating a barrier for treatment of
HSV infections, and has urged the development of new and effective pharmaceutical
agents. As of right now there are three classes of drugs that have proven to be efficient
for HSV treatment; acyclic guanosine analogues, acyclic nucleotide analogues, and
pyrophosphate analogues. With very little effective drug or vaccine treating this disease,
making it crucial to discover an effective HSV drug or vaccine needed to protect against
infection. Over the last two decades, glycoprotein D has been a promising candidate for
HSV, however many vaccines used in clinical trials have been unsuccessful.
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Table 1
Illustrates Examples of Currently Available Anti-Viral Drugs That Treat HSV
Name

Class

Oral
Bioavailability

Mechanism
of Action

Route of
Administration

Valacyclovir

Nucleotide
Analog

55%

Oral

Acyclovir

Nucleotide
Analog

10% to 20%

Famciclovir

Nucleotide
Analog

77%

DNA
Polymerase
Inhibitor
DNA
Polymerase
Inhibitor
DNA
Polymerase
Inhibitor

IV, Oral

Oral

2.3.2 Possible New Treatment
The entry of HSV requires the binding of the viral envelope protein gD to cell
surface receptors such as nectin-1. The movement of C-terminus from the surface of the
gD core, exposes a small hydrophobic pocket this is essential for nectin -1 binding. To
reduce the spread of infection from the herpes simplex virus, incorporating small
molecules into the binding site between gD and nectin-1 could disrupt the entry of the
virus into the host cell. Therefore, our experimental collaborator proposes to develop gD
inhibitor as a new treatment for HSV infection.
2.4 Computational Approach to Identify Lead Compounds.
Seeing that the interaction between gD/Nectin-1 as a promising target for the
treatment of HSV, structured-based drug design can be carried out to search for new
potential drug leads. In this research, potential drug candidates were searched through
using a high-throughput virtual screening method. This method screens over 17 million
commercially available compounds against the active site of gD. Potential compounds
were then screened experimentally using KOS cell culture and ELISA assay. From
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computer-aided virtual screening, two structurally similar compounds were identified to
inhibit the interaction between gD and nectin-1.
2.5 Methods
2.5.1 Ligand Preparation
The compounds were retrieved from the ZINC Drug-Like library (17,900,742
entries) in mol2 format. Empirical pKa was calculated to determine the favorable
tautomers and favorable protonation states at physiological pH=7. Then, these
compounds have been energetically minimized using the OPLS3 force field.
2.5.2 Protein Preparation
The three-dimensional structure of HSV Glycoprotein D (gD) was retrieved from
Protein Data Bank (PDB ID: 2C36). The structure was prepared using Protein
Preparation Wizard workflow in Schrodinger package, which consisted of three steps
(preprocessing, optimizing, minimizing). The minimization step used OPLS3 force field.
2.5.3 Site-Map
The protein structure went through the Schrodinger Site-Map ( version 2.8,
Schrödinger, LLC, New York, NY, 2013) to identify the active site of the protein [22].
The site-map generated a binding site that could be used for our study. We selected this
area based on its biological importance for gD/nectin-1 interaction. Figure 11 illustrates
the region selected to be used for our docking method.
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Figure 11
Top Ranked Site of gD (PDB:2C36) Binding Site Detection

Note. White spheres are site points, red color for H-bond acceptor, blue for H-bond
donor, and yellow for hydrophobic regions

2.5.4 High Throughput Virtual Screening
Virtual screening was carried out using the docking grid file generated from the
active site of the gD. The ligands from the ZINC Drug-Like library were docked into the
binding site of the gD with High-throughput virtual screening (HTVS) scoring function,
which reduced the 17 million compounds to 1700. The top 1700 compounds were moved
onto the next stage based on their HTVS docking score.
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2.5.5 Glide XP-Docking
The top 1700 compounds were further reduced to 20 compounds using Glide XP
scoring function. With the prepared receptor, the ligands were docked using Glide XP
docking protocol. Ligands were sorted and ranked based on the XP Glide score. The top
twenty compounds were selected from the Glide XP docking for MM-GBSA scoring.
2.5.6 Biological Data
Binding inhibition was carried out by our experimental collaborator (the
Krummenacher group) using competition ELISA. Purified gD(285t) protein preincubated with the indicated drugs at 1 or 5 mM was added to purified nectin-1 protein.
The amount of bound gD was detected by a polyclonal antibody and reported as the
percentage of binding in the absence of inhibitor. Our experimental collaborator further
carried out functional inhibition of infection using plaque reduction assay of HSV-1 KOS
on Vero Cells. Compounds dissolved in DMSO (100mM) were mixed with about 200
pfu/ml HSV-1 KOS in cell culture medium and incubated for 1h at RT. Then, 0,5 ml was
added to Vero cells and incubated for 1h at 37°C. Inoculum was removed and cells
overlaid with medium containing methylcellulose. After 48h infection, cells were stained
with crystal violet and plaques counted. Data show the percentage of plaques of an
average of 2 wells compared to untreated virus in each experiment.
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2.5.7 MM-GBSA Scoring
The top 20 compounds from the Glide XP docking were scored with the MMGBSA approach, as implemented in the Prime program in Schrodinger software suite.
The MM-GBSA would calculate the ligand binding (MM-GBSA dG bind) energy based
on this equation from Schrodinger:
dG bind =
E_complex(minimized) - E_ligand(minimized) - E_receptor(minimzed)

These top 20 compounds were ranked based on their MM-GBSA binding energy. The
MM-GBSA binding energy was further decomposed into key components including
electrostatic energy, Van der Waals (VDW), and hydrophobic interactions for further
analysis comparison.
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Figure 12
Overall Scheme of Virtual Screening Workflow for the Discovery of Novel gD Inhibitors

Ligand Preparation
> 17 million compounds were obtained from ZINC Database
Minimized in OPLS4 force field at physiological pH 7

Protein Preparation
HSV Glycoprotein D (gD) PDB: 2C36 was obtained from Protein Database
Preprocessed, optimized and minimized in OPLS3 force field

Site-Map
Schrodinger Site-Map program to determine optimal binding site

Virtual Screening by using the prepared ligand and receptor
Top 20% of compounds were selected based on scoring hits

Extra Precision (XP) Docking (1700 compounds)
Top 20 compounds were selected based on Glide Score

20 available compounds were validated by performing HSV-1 KOS on
Vero cells for inhibition and ELISA assay for binding inhibition

Two candidate compounds were evaluated on the inhibition of HSV

MM-GBSA was used to investigate their binding characteristics
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2.6 Results and Discussion
2.6.1 Outcomes of High Throughput Virtual Screening and Docking Studies
To discover and optimize potential ligand to inhibit gD/nectin – 1 complex
formation, a virtual screening of commercially available compounds (ZINC Database, >
17 million compounds) went through the Virtual Screening Workflow to determine
potential lead compounds from their chemical structure and docking capabilities against
HSV gD protein (PDB: 2C36). The compounds were identified based on their scores, to
proceed for in vitro testing to determine their biological activity. The two small
molecules that were identified had structural similarity and pharmacophore modelling
was used to define their structure-activity relationship. 20 compounds were selected
based on their HTVS and Glide XP docking score. Figure 13, illustrates the top 20
compounds binding to gD to reduce the interaction with nectin-1.
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Figure 13
Glycoprotein D (gD) (Green) and Nectin-1 (Blue) Interaction, Library of Compounds
Inserted in Between

Figure 14 shows the chemical structures of the top 20 ligands from the virtual
screening. There is a wide range of structural diversity within the generated compounds.
The compounds contain molecular weight ranging from 263.3 (g/mol) to 348.5 (g/mol).
With each compound possessing at least 3 hydrogen bond acceptors, up to 4 hydrogen
bond donor and 2 to 6 rotatable bonds per compound. Compounds 3, 10, 11, and 20 have
3 hydrogen bond acceptor groups with 5 rotatable bonds. Each compound contains one or
more aromatic rings structures, amide groups, ketones, primary amines, secondary
amines and tertiary amines are common similarities these structures have. These different
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functional groups are capable to bind differently within the binding pocket, allowing the
structure to bind tightly to the target structure. Compounds 3, 10 and 11 have the most
similarity between them compared to other compounds. Compound 9 also has some
similarity but contains an extra amide group at the para-position of the ring structure.

40

Figure 14
Illustrates the Top Twenty Compounds Obtained From the VSW
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2.6.2. Identification of Candidate Compounds by Virtual Screening and Molecular
Docking
Table 2, shows the different docking scores, binding free energy, and biological
activity of all the top 20 compounds. The XP docking score are given by how well the
compound is able to bind to the protein. The docking scores ranges from -4.147 to -5.504
kcal/mol. Compounds 3 and 11 had an above average docking score of -5.221 and -5.08
kcal/mol, respectively.
The docking score generates an accurate pose of each protein-ligand complex,
MM-GBSA binding energy is used to study binding energy of each complex. After
completing the VSW method, 20 compounds were selected to be tested by our
experimental collaborator to produce two lead compounds. The 20 compounds were then
re-scored using MM-GBSA binding energy (Figure 15). Compound 3 and 11 both have
high electrostatic interactions within the binding pocket. Compound 3 has a large
electrostatic energy change of -18 (kcal/mol), compared to compound 11 contains a least
favorable electrostatic energy change of -14 (kcal/mol). Another key similarity both these
compounds share is their large contribution to pi-pi stacking with other residues.
Compound 3 contains a large pi-pi energy interaction of -3.6 (kcal/mol), which is the
second highest pi-pi energy score of all the 20 compounds. Compound 11 however,
possess a smaller pi-pi energy interaction of -3.1 (kcal/mol). This pi-pi interaction could
be a good indication of successful binding for further optimization of future compounds.
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Table 2
Docking and Binding Free Energy Scores of Top 20 Compounds Generated From HTvS

Compound
Number

Docking
XP score

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

-5.109
-5.258
-5.221
-4.929
-4.17
-5.33
-4.808
-5.504
-5.207
-5.215
-5.08
-4.147
-4.292
-4.196
-4.981
-5.197
-5.283
-5.061
-5.00
-4.815

MMGBSA dG
Bind
(kcal/mol)
-63.843
-63.673
-63.073
-62.056
-61.586
-61.352
-61.008
-60.984
-60.923
-60.902
-60.898
-60.735
-60.673
-60.314
-60.249
-60.212
-59.541
-59.024
-58.987
-58.874

∆Eele
∆Epi-pi
∆EvdW
(kcal/mol) (kcal/mol) (kcal/mol)

HSV-1
KOS
inhibition

-2.306
-3.193
-3.662
-0.121
-1.200
-0.278
-0.555
-0.327
-3.006
-3.543
-3.154
-1.070
-0.803
-6.370
-0.140
0.000
-2.832
-1.592
-1.592
-2.024

+
+
+
-

-15.652
-10.326
-18.410
-5.177
-20.367
-16.926
-21.769
-4.508
3.057
-17.709
-14.466
-7.930
100.389
0.642
16.664
-17.112
-15.026
-33.218
-33.218
4.029

-33.354
-33.671
-27.838
-31.987
-29.853
-34.712
-22.959
-29.119
-31.542
-26.919
-26.087
-31.703
-31.104
-29.333
-25.703
-32.460
-28.267
-29.870
-29.870
-26.991

Note. Binding free energy data of top 20 compounds. ∆G (kcal/mol) = total binding
energy, ∆Eele (kcal/mol) = Electrostatic energy, ∆Epi-pi (kcal/mol) = pi-pi interactions,
∆EvdW (kcal/mol) = van Der Waals energy
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Figure 15
Correlation Analysis was Used to Calculate the Correlation Between the Glide XP
Docking Score and MM-GBSA Binding Free Energy (R=0.0214)
R² = 0.0214

XP GLIDESCORE (KCAL/MOL)
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2.6.3 Structure-Activity Analysis
We then used those same compounds to see if any of them have any biological
activity against the HSV-1 strains KOS. Only a few compounds showed any effect
toward the cell line. The protein-ligand complex of both compounds contain a similar
pose during simulation (Figure 16). The amide group for both compounds extends
outwards towards the N-terminus region. Both ring structures orient themselves over each
other, with the benzene ring resting on top of the other ring structure containing the alkyl
group Compounds 3 and 11 form hydrogen bond and aromatic interactions with the
residues in the binding site of gD. The aromatic ring structure containing a halogen atom
is interacting with TYR-234. This can be observed for both compounds. The benzene
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ring of compound 11 is also interacting with PHE-223 through pi-pi interaction.
Hydrogen bonds are formed between LEU-25 and the nitrogen of the amine of both
compounds. An additional hydrogen bond is formed with LEU-25 and the amine group of
compound 3. The oxygen of the amide group of compound 3 is forming a bond with the
side chain of GLN-27. LEU-25 and GLN-27 are critical resides for gD to form a N
terminal hairpin conformation [49]. Based on Figure 16, it can be inferred that both these
compounds have the ability to disrupt the formation of an N-terminal hairpin
conformation by its ability to interact with the gD active site and provide information
about the chemical structure to inhibit gD/nectin-1 formation.
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Figure 16
Binding Comparison of Top Two Compounds

Notes. Compounds 3 and 11 binding to glycoprotein D (PDB: 2C36) and residues they
interact with. LEU-25 and TYR-234 interact with both compounds. GLN-27 only
interacts with compound 3 and PHE-223 only interacts with compound 11. The poses for
each compound are very similar

2.6.4 Analysis of Atom-Based PHASE 3D-QSAR Models (QSAR Visualization)
In order to study the correlation with inhibitory activity of generated top
compounds, compounds 3 and 11 were further analyzed based on their important
structural features required for interaction of the ligand with the active site of the receptor
as shown in Figure 14. The colored spheres and torus represent the important structural
features of these compounds. Compounds 3 and 11 have a similar structure possessing a
2-amino-2-phenylacetamide core that contains a hydrogen bond acceptor (A1), two
hydrogen bond donors (D3 and D2), an aromatic ring (R7) and a positively ionizable
feature (P5/P6). The other ring structure attached contains an alkyl element at the -meta
position (Chlorine/Bromine) and at the -ortho position for compound 3 (Fluorine).
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Compound 10 shares the same similar structure as compound 11, except it does not
contain the methyl group that is placed on the carbon connecting the benzene ring and the
2-amino-2-phenylacetamide section. The addition of this methyl group did not give us
any biological activity.

Figure 17
Pharmacophore Features of 3 and 11

Note. Light blue spheres are hydrogen-bond donor, light red spheres are hydrogen-bond
acceptor, dark blue spheres are positively ionizable, green are hydrophobic region, and
orange torus are aromatic features. Compound 3 (left) and 11 (right) have a high
similarity in pharmacophore features, they have seven total similar pharmacophore
features with 1 additional hydrophobic region on the occupied benzene ring

2.7 Conclusion
This high throughput virtual screening method is a fast and easy method that
helps filter through millions of compounds to generate potential lead compounds. In this
study, we were able to discover two lead compounds that were obtained from a large
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library of compounds. By applying this computational technique against the crystal
structure of HSV gD (PDB ID: 2C36) we were able to filter out potential candidates to
bind the pocket of gD.
The second screening method detected 1700 compound by using standard (SP)
and extra precision (XP) mode of Glide docking software. The top 20 compounds were
selected to observe their inhibitory functions by our experimental collaborator.
In this chapter, we applied a novel method of virtual screening, to determine
which set of small molecules could bind to binding pocket. Our target for this study was
the gD protein that plays a critical role in mediating the virus into the cellular envelope.
Currently, there is no cure for HSV, and finding an efficient way to stop the spread of the
disease by using computational methods has become a valuable role in finding a
promising drug. The results show that the general screening was a success and was able
to accumulate a reasonable amount of lead compounds. Of the 20 compounds that went
through the docking protocol, we were able to obtain two likely candidates as
pharmaceutical agents for treating HSV. The top two compounds will be optimized to
observe how changes to their structure could help improve their efficacy.
2.8 Future Works
After generating two compounds from the VSW and experimental data, we can
further optimize and adapt different methods to increase the docking score and inhibitory
activity from these compounds. With the useful information about the detailed interaction
between gD and these two compounds had allowed us to create potential inhibitors for
blocking gD/nectin-1 complex formation and HSV-1 entry and infection.
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2.8.1 Optimize Ligand to Increase Docking Score
Compound 3 and 11 are structurally similar and have been found to produce a
biological response against HSV-1 infections. Although these compounds are able to
inhibit infection of Vero cells at sub-mM concentration, their efficacy needs to be
improved. To improve their affinity and efficacy for gD, we will synthesize and test
derivatives of one of the compounds. Majority of the chemical structure has been set
based off compound 11, both the benzene rings will be altered by the addition of the
seven functional groups in Figure 18.

Figure 18
Seven Functional Groups Usable on Compound 11

2.8.2 Link Compound from Site 1 to Compound at Adjacent Site 2 to Improve
Inhibitory Capabilities
Another way to improve the inhibitory capabilities of compounds binding to site 1
is to introduce a linker to the compound to be used as an anchor at the adjacent site 2, see
Figure 19. Compound ST21 is a compound that was selected from ZINC Drug-like
library for its high docking score during the VSW on site 2 of HSV-1 gD. ST21 does not
need intrinsic antiviral activity to be valuable molecule to anchor an active inhibitor
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against site 1. The number of linkers that connect the two compounds were based on
relative orientation of both compounds docked to their respective site. By linking ST21
with the top compounds from this research, we can improve the docking capabilities by
synthesizing a new novel linked compound and biological testing its activity by our
experimental collaborator.

Figure 19
Design of a Linked Compound Against Sites 1 and 2

Note. A. Structure of the HSV-1 gD-nectin-1 complex (PDB ID:3SKU). With the
location of Site 1 and 2 identified by the gray and purple boxes. The structure of a linked
compound candidate is shown as filled spheres. B. Structure of a candidate linked
compound based on Site 1 active compound #12 (gray box) and compound S2T1, which
has a high docking score for Site 2 (purple box). Both compounds are connected by a
linker
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Chapter 3
Dopamine D4 Receptor
3.1 Introduction
The dopaminergic system has been extensively studied due to its prominent role
in modulating cognitive and motor behavior[50]. Dopamine receptor plays a critical role
in cell signaling process by regulating neuronal pathways responsible for locomotion,
cognition, and memory. The dopamine receptor is located in various areas of the brain.
The dopamine receptor is part of a large Class A G-protein-coupled receptor superfamily,
containing five different subtypes. These five subtypes are classified into D1-like and
D2-like receptor families. The D1 and D5 receptors are D1-like and D2, D3, and D4
receptors are D2-like receptors. In this chapter, I will be focusing on the D4 receptor
(D4R) and the experiments that were carried out on it.
3.2 Dopamine Receptor
The dopamine receptors are located in different areas of the brain such as the
frontal cortex, substantia nigra, ventral tegmental area (VTA) and hypothalamus. These
areas of the brain are linked to cognitive function, motor function, memory, and alcohol
abuse.
3.2.1 Background of Dopamine Receptor
The dopamine receptor is a G protein coupled receptors (GPCRs) that is involved
in regulation of motor activity and cognitive behavior. Many neurological and
neurodegenerative disorders such as Schizophrenia, Tourette’s Syndrome, Parkinson’s
disease, bipolar disorder, Alzheimer’s disease, attention-deficit/hyperactivity disorder and
Huntington disease are believed to be linked to the dopamine receptor.[51] Dopamine is
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a monoamine catecholamine neurotransmitter and binds to five distinct dopamine
receptors, D1 to D5, which is classified as D1-like receptors (D1 and D5) and D2-like
receptors (D2, D3, and D4).[52] The D1-like receptors are coupled to GS/olf proteins to
mediate induction of adenylyl cyclases (AC) and produce cyclic AMP (cAMP) as a
secondary messenger. The D2-like receptors (D2, D3, and D4) are primarily coupled to
inhibitory Gi/o proteins and inhibit adenylyl cyclase.[53] Another receptor signaling
pathway that is activated from the D2-like receptor is the Beta-Arrestin pathway. This
pathway is another intracellular pathway that has the ability to mediate distinct
physiological pathways by signaling cascades leading to glycogen synthase kinase-3
(GSK) activation and downstream signaling. [54][55] Both these signaling pathways are
activated by small molecule and can show bias signaling to mediate distinct physiological
responses. Figure 20 illustrates the mechanism of the GPCR when a ligand is bound to
the receptor and influence a downstream reaction to one of the biological pathways.
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Figure 20
A Cartoon Representation of the Different Effects Ligands on GPCR

Extracellular

Ligand

GPCR
Intracellular

GDP
Β-arrestin
Gα

Gγ
Gβ
Note. The binding of small molecules to the active site can influence a change in affinity
and/or bias GPCR coupling to a particular intracellular partner. Following the blue arrow,
is the G-protein complex containing Gα, Gγ, Gβ and GDP in blue, purple, yellow and
red, respectively. Following the orange arrow is the Beta-arrestin pathway in orange

The Dopamine D4 (DRD4) is a sub-type of class D2 receptor, inhibiting
adenylate cyclase via Gi/o-proteins. Though the D2-like receptors belong to the same
class, their genetic make-up differs from each other. The dopamine D2-like receptors
show high relationship between the three in sequence similarity and sequence identity.
From Table 3, show the percent similarity and percent identity between the D2-like
receptors. The D4 receptor has been linked to many physiological diseases like
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Schizophrenia, Parkinson’s disease, Huntington’s disease, and Attention Deficient
Hyperactivity Disorder. Once a small ligand is introduced to the binding site of the
receptor, it will influence on conformational change on the receptor, resulting in a
cascade of two possible pathways. One being the G-protein mediated pathway and the
other the B-arrestin pathway.

Table 3
Similarity and Identity Of D2 (PDB ID: 6CM4), D3 (PDB ID: 3PBL), and D4 (PDB ID:
5WIU) After Multiple Sequence Alignment
D2

D3

D4

D2

x

71

47

D3

81

x

48

D4

63

64

x

Note. Similarities in term of percentage (%) are on the lower-left side of the table, and
identities on the upper-right

3.2.2. Novel Compounds Binding and Structural Profile
Keck et al. have synthesized and tested in vivo the binding affinity, binding
efficacy and selectivity of a novel set of compounds. These compounds were derived
from the parent compound A-412997. A-412997 is a partial agonist, with high selectivity
for the D4R. They were able to generate 3 different classes of compounds based on their
structural modifications derived from A-412997. Each class consist of two compounds,
each compound has a different addition or substitution that is different from the other
compounds. Though these compounds were able to be studied and identify their efficacy
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profile, their docking poses still remain unknown. To understand more about the reason
why these compounds behave the way they do, we applied Molecular Dynamics (MD)
simulation to shed light onto this mystery.
A set of novel compounds have been developed to study their biological activity
and ligand efficacy on D4R by our collaborator. Seven compounds were identified based
on their efficacy profile to D4 receptor (Figure 21). A-412997 is the parent compound
that is characterized a full agonist at D4R and high selectivity over the other D2-like
receptors, D2R and D3R. Six compounds derived from A-412997 possess different
efficacy profile on all D2-like receptors. The six compounds were separated based on
their structural modification. Class I has a change in piperidine ring, Class II has a
substitution of the pyridine ring for phenyl or napthyl, and Class III has a para-substituted
pyridine ring. These modifications influence a different selectivity and efficacy profile,
however their binding interactions has yet to be understood. By using molecular dynamic
simulation, we were able to identify different positions, orientations, and interactions the
seven compounds influenced on the D2- like receptors.
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Figure 21
Three Classes of Modification to the Structure of A-412997 Result in Differing Binding
and Efficacy Profiles at D2-Like Receptor

Note. The arrows indicate the position that was modified on the parent structure A412997. (A) (Class I) Substitution of piperidone ring. (B) (Class II) Substitution of
pyridine ring with phenyl or napthyl moiety. (C) (Class III) Para-substituted pyridine
rings. These features are indicated in dashed circles and binding/efficacy profiles are
described in the dashed boxes [56]

In Table 4 and 5, illustrates the efficacy and affinity of the seven novel
compounds. These values were obtained from Keck et al.[56] The parent compound, A412997, shows a 115-fold and 31-fold higher affinity for D4R over D2R and D3R,
respectively, measured by our experimental collaborator. Class 1 compounds, CAB02 56

140 and CAB02-017, are defined by the replacement piperidinyl ring of A-412997 with a
piperazine, resulted in similar binding and agonist efficacy profile for D4R. Class 1 also
resulted in improved subtype selectivity and efficacy for D2R and D3R. Class 2
compounds, CAB03-015 and CAB02-11, are defined by the replacement of the pyridinyl
ring of A-412997 with a phenyl or napthyl moiety. Class 2 resulted in improved subtype
selectivity, diminished efficacy partial agonist profile at D4R, and had no measurable
agonist efficacy at either D2R or D3Rs. Class 3 compounds, CAB02-003 and CAB02005, are defined as a para-substitution on the pyridinyl ring of A-412997. Class 3 resulted
in a complete loss of all agonist efficacy but was still retained high-affinity of binding at
D4R, with minimal binding at D2R and D3R. An overview of the binding affinity and
efficacy of compounds with classes 1 – 3 are listed in Table 4 - 5. To understand the
modest changes each compound possess against the D2-like receptors, MD simulation
was performed to identify interactions within the binding site of the receptor and various
poses of the compound that play a crucial role in agonist selectivity and efficacy.
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Table 4
Binding Affinities of Novel Compounds and Six Derivatives to the D2-Like Receptor Binding Data in HEK293 Membranes for
Ligand
Compounds

Ki (nM) ± SEM
[3H]N-methylspiperone

Ki (nM) ± SEM
[3H] -(R) -(+)-7-OH-DPAT

D2 Ki

D3 Ki

D4 Ki

D2/D4

D3/D4

6250 ±
375

1680

54.2 ±
7.01

115

31

Class I
CAB02 – 140

>10,000

>10,000

212 62.9

>47

>47

CAB02 – 017

>50,000

>50,000

67.9 ± 24

>736

>736

Class II
CAB03 - 015

821 ± 34.9

433 ± 137

32

17

CAB02 - 011

1489 ± 95

11,459 ±
3085

25.8 ±
9.01
28.4 ± 8

52

402

Class III
CAB02 – 003

>50,000

>50,000

95 ± 26

>526

>526

A-412997

D2 Ki

D3 Ki

D4 Ki

251±72.2 167±38.8 3.95±1.41

D2/D4

D3/D4

64

42

58

3320 ±
450
603 ±
220

6480 ±
972
1490 ±
275

1.89 ±
0.38
2.23 ±
0.93

1757

3429

270

668

127 ±
35.8
200 ±
38.1

777 ±
141
1246 ±
195

1.4 ± 0.42

91

555

1.65 ±
0.21

121

755

>10,000

>10,000

12.5 ±
>800
>800
1.85
CAB02 - 005
>50,000
>50,000
41.7 ±
>1198
>1198
>10,000 >10,000
6.87 ±
>1455 >1455
7.0
0.73
Note. Ki values determined by competitive inhibition of [3H]N-methylspiperone or [3H]-(R)-(+)-7-OH-DPAT binding in
membranes harvested from HEK293 cells stably expressing hD2R, hD3R, or hD4R. All Ki values are presented as means ±
SEM.[56]

Table 5
Efficacy as Measured via Modulation of cAMP Accumulation and Beta(β) – Arrestin Recruitment
Compounds

Β-arrestin Recruitment

cAMP
Accumulation

59

D4R cAMP
Emax %
61.9 ± 4.7

D2R - β-arr
Emax %

D3R - β -arr
Emax %

D4R - β -arr
Emax %

A-412997 -1

D2R cAMP
Emax %
Inactive

Inactive

ND

22.5 ± 3.98

Class I
CAB02 – 140 - 10
CAB02 – 017 - 21

18.96 ± 5.2
18.80 ± 8.19

3.6 ± 1.3
58.0 ± 1.8

23.9 ± 5.1
18.7 ± 0.4

49.4 ± 2.0
44.7 ± 5.9

30.7 ± 6.4
26.2 ± 5.1

Class II
CAB03 – 015 - 6
CAB02 – 011 - 13

Inactive
Inactive

32.9 ± 3.9
27.8 ± 8.4

Inactive
Inactive

Inactive
Inactive

14 ± 0.3
16.4 ± 3.9

Class III
CAB02 – 003 - 12
CAB02 – 005 - 9

Inactive
Inactive

Inactive
Inactive

Inactive
Inactive

Inactive
Inactive

Inactive
Inactive

Note. Values determined by nonlinear regression of individual experiments run in triplicate as detailed in materials and
methods under cAMP accumulation and Beta-Arrestin assays. All Emax values are presented as means ± SEM; n = 3−4.
Inactive indicates no measurable activity in indicated assay. b A measure of agonism as defined by the maximum inhibition of
cAMP observed for each compound. c A measure of antagonism as defined by the maximum blockade of dopamine mediated
cAMP inhibition by each compound.[56]

3.2.3 Molecular Dynamics Simulations
To identify the difference in binding modes of novel compounds with structural
modifications to the parent compound, we unveil peculiar interactions, various binding
positions, and dynamic properties that could have differential effects on the D4 receptor.
A computational approach that demonstrates how these three classes of compounds can
be classified according to their specific interactions within the binding cavity. We
propose a computational protocol of molecular docking to the D2-like receptors which
considers the flexibility involved of the binding process. Cluster analysis was used to
determine the best ligand-receptor complex, simulation interaction diagram to specific
residues that play a critical role in binding of these three distinct classes of compounds. In
this computational analysis, all the molecules had different binding interactions than the
parent protein. Furthermore, their docking poses are also different which could correlate
to their biological activity. To date there are no current MD simulation done on A412997. Recently, Haixia Ge, et al used MD simulation on the D1 and D2 receptor to
analyze study the interaction of a potential candidate for treatment of anxiety and
depression. Their studies provided new insight on the structural and functional
relationship of binding two enantiomers to the dopamine receptors [57]. Ferraro M. et al,
used MD simulations and machine learning to gather information on a set of compounds
to investigate their structure-efficacy relationships on the D3R. With the modifications
made to each compound, the structurally similar molecules were resulted in different
efficacy profiles based on their interactions and conformational changes to the receptor in
hopes of designing new ligand to link to their pharmacological profile. [58]
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3.2.4 Ligand Effecting the Confirmation of Receptor
From the docking simulation, the seven compounds bind different from one
another due to their different chemical structure. Inside the binding pocket, different
interactions occur with the neighboring residues and result in a different binding pose
from the other compounds. We identified the different residues interacting with each
compound, various poses that differ between the ligand, receptor, and ligand-receptor
complex to relate to their efficacy profile.
3.3 Methods
There are many computational methods we plan to explore for this chapter. The
GPCR involves many steps since it is a membrane bound receptor, its structure needing
to be analyzed and prepared for simulation.
3.3.1 Ligand Preparation
Each ligand was first constructed in Chemdraw and extracted as a mol2 file. The
mol2 files were then uploaded to maestro for further preparation. Each molecule went
through an optimization, hybridization, and empirical pKa step. The most ionizable
structure was selected to be docked against the prepared protein.
3.3.2 Receptor Preparation
The dopamine D4 receptor contains 422 residues and has multiple small
molecules present in its crystal structure. The structure and sequence were obtained from
the Protein Data Bank (PDB: 5WIU). After we removed all of the unnecessary
molecules, the crystal ligand and receptor was ready for further preparation. The ICL3
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contains a long variable number tandem repeat sequence, and was truncated for
simulation. The structure went through minimization, optimization and hybridization
steps. Due to some errors found within the protein, homology modeling was used to
reduce these errors.
3.3.3 Homology Modeling
Homology modeling is a popular computational method used to predict protein
structure. This technique uses two proteins that come from the same common ancestor, in
this case D2 and D4, their PDB files are 3PBL and 5WIU, respectively.
3.3.4 Grid Generation
Having the receptor fully prepared and structure modified correctly, we
determined the binding site from crystal ligand present in the structure. From the crystal
complex, the crystal ligand was selected as our docking site of interest.
3.3.5 Induced Fit/Desmond Setup/MD Simulation
The induced fit docking (IFD) method takes into account the flexibility of both
the ligand and the receptor. All protein-ligand complexes were generated, each docking
simulation taking about 100 nanoseconds.
3.3.6 Clustering
Clustering analysis is done on the complex to observe the most abundant ligandprotein conformation during MD simulation. The clustering method took multiple
snapshots of the complex during the simulation, about 1000 snapshots, and clusters them
all together to determine which confirmation is correlating with the highest score. The
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most abundant cluster frame is compared between the other complexes to see if there are
any similarities between the parent compound and the six compounds within of the three
classes.
3.3.7 Simulation Interaction Diagram (SID)
The simulation interaction diagram tells provides a visual and analytical view
during the simulation. The SID step has multiple analysis to validate our findings, it
includes Protein-Ligand RMSD (Eq. 1), Protein RMSF and Ligand RMSF (Eq. 2),
Protein Secondary Structure, Protein-Ligand Contacts, and Ligand Torsion Profile
(Figure 22). The movement of the ligand and protein are summarized in this section and
will discuss more in depth in the discussion section.
1

′
2
𝑅𝑀𝑆𝐷𝑥 = √𝑁 ∑𝑁
𝑖=1 (𝑟𝑖 (𝑡𝑥 )) − 𝑟𝑖 (𝑡𝑟𝑒𝑓 ))

1

𝑅𝑀𝑆𝐹𝑥 = √𝑇 ∑𝑇𝑡=1 < (𝑟𝑖′ (𝑡)) − 𝑟𝑖 (𝑡𝑟𝑒𝑓 ))2 >
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Eq. 1

Eq. 2

Figure 22
Compound A-412997 and Labeled Dihedral Angles From SID

Note. From the parent structure there are 5 dihedral angles that rotate during simulation
labeled 1 to 5. In blue displays the 2-(Piperidin-4-yl) pyridine ring and in red is the
benzene ring

3.4 Results and Discussion
3.4.1 Molecular Dynamics Studies
To uncover the structure-activity relationship of novel D4 ligands, a set of seven
compounds synthesized by Keck et al (A-412997, CAB02-140, CAB02-017, CAB03015, CAB02-011, CAB02-003 and CAB02-005) were docked to the crystal structure of
D2R (PDB ID: 6CM4), D3R (PDB ID: 3PBL) and D4R(PDB ID: 5WIU) and then
subjected to a 100ns MD simulation followed by SID and clustering analysis described in
the previous section. A representative ligand from each class modification is presented to
validate our results. The summary of structural and dynamical properties from the MD
simulation of the three class modifications are gathered to compare against A-412997.
Although the same class modifications cause a similar change in the majority of the
properties, the subtle differences are also identified.
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3.4.2 Docking Validation
Receptor coordinates of the human D2, D3, and D4 crystal structure in complex
with risperidone (PDB ID: 6CM4), eticlopride (PDB ID: 3PBL) and nemonapride (PDB
ID: 5WIU), respectively, were retrieved from the PDB and use for docking to validate
our findings. In Figure 23 to 26, shows the crystal structure and Glide XP docking pose
of each complex. Very little movement has changed between the two ligand poses within
the docking site of all three receptors. The simulation of each crystal ligand with it
respected receptor gave high confidence in our results from the presented figures.

65

Figure 23
Comparison of the Crystal Pose (Red) and the Glide XP Docked Pose (Blue) of Crystal
Ligand Risperidone in D2 Receptor (PDB 6CM4)

90

90

Note. Both structures of risperidone are place in pocket with the two aromatic groups
facing toward the extracellular loops and the single loop submerged in the center of the
receptor
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Figure 24
Comparison of the Crystal Pose (Red) and the Glide XP Docked Pose (Blue) Of
Eticlopride in D3 Receptor (PDB 3PBL)

90

90

Note. Both structures of eticlopride are overlapping each other with very little difference
in docking poses to the receptor
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Figure 25
Comparison of the Crystal Pose (Red) and the Glide XP Docked Pose (Blue) of
Nemonapride in D4 Receptor (PDB 5WIU)

90

90

Note. The benzene ring of nemonapride overlaps with the each other and the disubstituted aromatic ring shows minor difference due to the molecules large size

3.4.3 Check Convergency of MD Simulation
To show that the simulation was a success, RMSD between the ligand and
receptor was analyzed during the 100 ns MD simulation. In Figure 26, shows the
stability of protein-ligand complex of A-412997 and the D2-like receptors by comparing
RMSD with respected to unbound protein structure. The plot exhibited both ligand and
protein were stable during the whole simulation run and formed stable complex. The
other RMSD figures can be found at the Supplementary Figures S4 to S6.
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Figure 26
Illustrating RMSD Plot Obtained From 100 ns MD Simulation Run

B

A

C

Note. (A) RMSD plot of the A-412997 (D2) (B) RMSD plot of the A-412997 (D3). (C)
RMSD plot of the A-412997 (D4). X and Y axes represent time (ns), and root means
square deviation (RMSD), respectively

3.4.4 Binding Comparison/Key Residue
All the compounds have an interaction ASP-1143.32, CYS-1183.36, ILE-184ECL2
within D2R, and aromatic residues TRP-3866.48, PHE-3896.51 and PHE-3906.52 located in
TM6 in Figure 27. Residues LEU-942.64, TRP-100ECL1 and PHE-1103.28interact with all
the synthesized compounds and forms two hydrogen bonds with ASP-1143.32 on D2
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(Figure 28) which persisted at above 120% for these compounds. There is a significantly
lower interaction with ASP-1143.32 for the parent compound A-412997 which persisted at
9% (Table A1). Compound CAB02-140 forms a pi bond with PHE-1103.28 on the
aromatic ring, and compound CAB03-015 forms a pi bond with TRP-3866.48. The
conserved residues on TM5 SER-1975.46 is crucial to form structural basis of agonist and
partial agonist activity on D2 receptor. Class 1 drugs can interact with this residue due to
the additional nitrogen group in the 1-(2-pyridyl) piperazine, limiting the rotation of the
compound.
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Figure 27
2D-interaction During MD Simulation Against D2R
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Note. (A). A-412997, (B-C) Class I compounds: CAB02-140 and CAB02-017, (D-E)
Class II compounds: CAB03-015 and CAB02-011 and (F-G) Class III compounds:
CAB02-003 and CAB02-005. Only contacts present at least 30% of the simulation time
are shown. Percentage of the interaction time with protein is written by the interaction
arrow
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Figure 28
The Fraction of Ligand-Protein Interaction Time for Protein Residues During MD
Simulation Against D2R
A

B

C

D

E

F

G

Note. (A) A-412997, (B-C) Class I compounds: CAB02-140 and CAB02-017, (D-E) Class
II compounds: CAB03-015 and CAB02-011 and (F-G) Class III compounds: CAB02-003
and CAB02-005
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In Figure 29, CAB03-015 does not form any type of bond with ASP-1103.32,
while the other compounds are able to bond with ASP-1103.32. All compounds interact
with LEU-892.64, VAL-1073.29, ASP-1103.32, PHE-3456.51, HIS-3496.55 and TYR-3657.35.
Class I is the only group where both compounds form a pi-pi interaction with one of the
aromatic residues (Figure 29). From the histogram in Figure 30, compound CAB03-015
has a significantly low interaction with ASP-1103.32 that persisted for 26.3% (Figure A2)
during the simulation run. CAB03-015 is also missing another crucial interaction with
PHE-1063.28 and can interact with other residues that other compounds do not like VAL180ECL2 and ASN-3526.58. PHE-3466.52 does not interact with CAB02-140 but does
interact with the rest of the compounds. The Class II and III compounds interact with
VAL-1895.39, a residue near the top of TM 5. The other compounds had an interaction of
100% or higher with ASP-1103.32 (Figure A2).
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Figure 29
2D-Interaction During MD Simulation Against D3R
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Note. (A) A-412997, (B-C) Class I compounds: CAB02-140 and CAB02-017, (D-E)
Class II compounds: CAB03-015 and CAB02-011 and (F-G) Class III compounds:
CAB02-003 and CAB02-005. Only contacts present at least 30% of the simulation time
are shown. Percentage of the interaction time with protein is written by the interaction
arrow
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Figure 30
The Interaction Fraction of Ligand-Protein Interaction Time for Protein Residues During
MD Simulation Against D3R
A
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Note. (A) A-412997, (B-C) Class I compounds: CAB02-140 and CAB02-017, (D-E)
Class II compounds: CAB03-015 and CAB02-011 and (F-G) Class III compounds:
CAB02-003 and CAB02-005
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Except for CAB03-015, all the compounds form two hydrogen bonds with ASP-1153.32
(Figure 31). Only two residues are observed to interact with all the compounds during
the simulation; TRP-101ECL1 and HIS-4146.55 (Figure 31). There is a large spread of
interaction that occur on TM3 for all the compounds. A-412997, CAB02-017 and
CAB02-011 interact with the same residues on TM3 but the other compounds interact
with one or two less than found between these three compounds Figure 31. Except for
CAB03-015, all the compounds form two hydrogen bonds with ASP-1153.32. A-412997 is
the only compound to interact with residue SER-1965.42 and SER-1975.43 on D4 during
simulation. The Class 1 compounds interact with residues on TM6 and 7 helices, PHE4106.51, PHE-4116.52, HIS-4146.55, and TYR-4387.43. The class 3 compounds interact with
a group of residues that are found on ECL2; CYS-185ECL2, ARG-186ECL2, and LEU187ECL2.
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Figure 31
2D-Interaction During MD Simulation Against D4R
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Note.(A) A-412997, (B-C) Class I compounds: CAB02-140 and CAB02-017, (D-E)
Class II compounds: CAB03-015 and CAB02-011 and (F-G) Class III compounds:
CAB02-003 and CAB02-005. Only contacts present at least 30% of the simulation time
are shown. Percentage of the interaction time with protein is written by the interaction
arrow
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Figure 32
The Interaction Fraction of Ligand-Protein Interaction Time for Protein Residues During
MD Simulation Against D4R
A
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Note. (A) A-412997, (B-C) Class I compounds: CAB02-140 and CAB02-017, (D-E)
Class II compounds: CAB03-015 and CAB02-011 and (F-G) Class III compounds:
CAB02-003 and CAB02-005
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3.4.5 MD Simulation Analysis
For the simulation, the run generated multiple complexes, with various
conformational poses for ligand and receptor. The top confirmation of each run was
selected by using a clustering analysis method which calculated the best favorable and
energy favorable ligand-receptor complex from the simulation. The top clusters were then
superimposed against the parent complex. The parent ligand was compared with the set
of ligand to observe any similarities or changes between the two complexes.
In Figure 33, shows the alignment between A-412997 and CAB02-140 following
molecular dynamic simulation of the D2R. For A-412997 it is positioned away from
TM3, lacking the main interaction with ASP-1143.32 and is positioned in between TM5
and TM6 to form pi bonds with PHE-3906.52 and PHE-1985.47 with the toluene group,
respectively. Although the structural difference between A-412997 and CAB-202-140 is
only piperadine versus a piperazine ring, their orientation of CAB02-140 has dramatically
shifted within the binding pocket. The piperazine ring is interacting with TRP-3866.48 and
PHE-3906.52 through pi-pi interaction for CAB02-140.
The class I compounds are flipped and shift toward TM3, 2 and 1. Near the
intracellular portion of the receptor, TM6 moves slightly inward and to the side with
TM7 moving slightly out. For the class II compounds, TM6 is slightly moved inward
compared to the parent compound. CAB03-015 shifts closer to TM3, 2 and 1 and
interacts with SER-1935.42 on TM5. For the class III compounds, TM6 moves slightly
inward and the toluene ring of both compounds is positioned to the other side of the
binding pocket. CAB02-003 shifts closer to TM2 and CAB02-005 shifts closer to TM7
forming a pi bond with TRP-3866.48.
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Figure 33
Superimposition of Most Abundant Ligand-Protein Complex During MD Simulation for
D2R
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Note. (A) A-412997 complex (red for ligand and yellow for receptor) and CAB02-140
(blue for ligand and purple for receptor). (B) Superimposition of ligand. (C) Complex of
A-412997/D4 with interacting residues. (D) Complex of CAB02-140/D2 with interacting
residues. (E-F) 2D interaction diagram of A-412997 and CAB02-140 from snapshot
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CAB02-140 is also flipped completely in D3R compared to A-412297 in Figure
34. The piperazine ring fo CAB02-140 is extends out toward TM7 compared to A412997 which closely interacts with the residues of TM3. ILE-183ECL2 forms a hydrogen
bond with the oxygen of CAB02-140, which allows the ring structure to form an aromatic
interaction with HIE-3496.55 on TM6, which is a conserved interacting residue at
orthosteric binding site of D3R.
For the D3 receptor, class 1 compounds influence a minimal change on ECL2
with a reduce fluctuation on ICL2 for CAB02-140 and ECL3 for CAB02-017 (Figure
35). With ECL2 being connected with TM5, this include influence a change in its
position as well, influencing a chain reaction for ICL3. Similar change in ECL2 for
CAB03-015 and CAB02-108 are observed, though they do not have a large fluctuation
toward the end of ICL3, which is involved in the activation of G-protein and Betaarrestin.
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Figure 34
Superimposition of Most Abundant Ligand-Protein Complex During MD Simulation for
D3R
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Note. (A) A-412997 complex (red for ligand and yellow for receptor) and CAB02-140
(blue for ligand and purple for receptor). (B) Superimposition of ligand. (C) Complex of
A-412997/D3 with interacting residues. (D) Complex of CAB02-140/D3 with interacting
residues. (E-F) 2D interaction diagram of A-412997 and CAB02-140 from snapshot
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Figure 35
Root Mean Square Fluctuation (RMSF) During MD Simulation

Note. (A) A-412997/D4R complex (red) and CAB02-140/D4R complex (blue). (B) A412997/D4R complex (red) and CAB02-017/D4R complex (blue). The image above
represents the different helices and loop regions of the receptor. The shaded parts (blue)
represent the difference between the two complexes
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Even with the addition of a ring structure to CAB02-011, it is still able to bind
similarly as A-412997 in Figure 28. Although, with the addition of another ring
structure, another striking difference we can see is that more aromatic residues are
oriented closer CAB02-011 than A-412997. TYR-3657.35 is also interacting with CAB02011, a residue that isn’t seen to interact with the parent compound at all.

84

Figure 36
Superimposition of Most Abundant Ligand-Protein Complex During MD Simulation for
D4R for A-412997 and CAB02-011
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Note. (A) A-412997 complex (red for ligand and yellow for receptor) and CAB02-011
(blue for ligand and purple for receptor). (B) Superimposition of ligand. (C) Complex of
A-412997/D4 with interacting residues. (D) Complex of CAB02-011/D4 with interacting
residues. (E-F) 2D interaction diagram of A-412997 and CAB02-011 from snapshot
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The addition of a methyl group at the para position on the pyridine ring of
CAB02-005 influences a flipped orientation of the ligand, positioning the arylamide
deeper into the binding pocket. The deeper insertion allows for HIS-4146.55 to interact
with the ring structure, forming a pi-pi bond with the arylamide group in Figure 37.
Compared to the D2 and D3 receptor, A-412997 is able to have both nitrogen groups
interact with ASP acid within the active site of the receptor.
In D4 receptor, A-412997 is oriented itself around TM3 allowing for a strong
interaction with ASP-1153.32 on TM3. All the compounds form a strong interaction with
ASP-1153.32. Class I compounds are shifted slightly below the parent structure and TM7
moves slightly inward for CAB02-017 D4 complex in Figure 38. CAB03-015 is crisscross over the parent drug and is in a linear orientation compared to the other compounds.
There is also a slightly shift in TM3 and TM5 for CAB02-015. TM8 in the CAB02-011
D4 complex is position in a downward formation. The class III drugs are oriented in a
similar position with a shift in TM5 in Figure 39.
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Figure 37
Superimposition of Most Abundant Ligand-Protein Complex During MD Simulation for
D4R for A-412997 and CAB02-140
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Note. (A) A-412997 complex (red for ligand and yellow for receptor) and CAB02-140
(blue for ligand and purple for receptor). (B) Superimposition of ligand. (C) Complex of
A-412997/D4 with interacting residues. (D) Complex of CAB02-140/D4 with interacting
residues. (E-F) 2D interaction diagram of A-412997 and CAB02-140 from snapshot
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Figure 38
Superimposition of Most Abundant Ligand-Protein Complex During MD Simulation for
D4R for A-412997 and CAB02-140

Note. (A) A-412997 complex (red for ligand and yellow for receptor) and CAB02-140
(blue for ligand and purple for receptor). (B) A-412997 complex (red for ligand and
yellow for receptor) and CAB02-017 (blue for ligand and purple for receptor. The arrow
illustrating the movement of the class 1 ligand and dashed circles representing the
different location of the receptor
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Figure 39
Superimposition of Most Abundant Ligand-Protein Complex During MD Simulation for
D4R for A-412997 and CAB02-003
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Note. (A) A-412997 complex (red for ligand and yellow for receptor) and CAB02-003
(blue for ligand and purple for receptor). (B) A-412997 complex (red for ligand and
yellow for receptor) and CAB02-005 (blue for ligand and purple for receptor. The arrow
illustrating the movement of the class 1 ligand and dashed circles representing the
different location of the receptor
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3.4.6 Table Assessment
Table 5 to 7 show D2-like receptors and the novel ligand changes compared to
the docking simulation of A-412997. Class 1 to 3 are colored in red, black and blue,
respectively. The data table illustrates any correlations between ligand activity, receptor
activity, and ligand-receptor binding interaction. Figure 22 illustrates the two-ring
structure.
For the Class 1 compounds, their biological activity is different from the other
compounds for the D2 and D3 receptor as partial agonist activity. These compounds
don’t influence any significant movement for TM7 for the D2 receptor. The other
compounds do interact with TM7 and have inactive properties. TM5 and TM6 show
some fluctuations for all the compounds for D2R. All except compound CAB03-015,
overlap with the single ring of A-412997 in the pocket. Even though both compounds for
class 1 have the same activity, their docking poses are different for D3R. CAB02-140
single ring and double ring group overlap with the parent compound, but it does flip like
the other structures. This could suggest that the compound has a different docking pose
compared to the other compounds.
For the class 2 compounds, their biological activity is the same for the D2 and D3
receptor for inactive activity, with D4 showing a weaker partial agonist activity. In the
D2 receptor, there is a slightly different docking pose for CAB03-015 compared to the
other class 2 compound. The compound does not flip and has a greater overlap for the
single ring compared to the parent compound. Both compounds influence a change on the
receptor for TM5, 6, and 7 and ECL1, ECL2, and ICL3 for the loops of the receptor. In
D3 and D4, both compounds influence a different helical shift on the receptor. CAB0290

011 possessing more variety in helical shift in D4, with TM3,4,5 and 6 changing its
position based off A-412997 binding.
For class 3, their biological activity is the same for D2 and D3 receptor for
inactive activity, with D4 showing antagonist activity. Both compounds have similar
binding poses for D2 and D3, with a slight change in D4 receptor docking pose. With
their ability to flip within the binding pocket could result into their antagonist activity, as
well as their interaction and movements of the residues and helices within the D4
receptor, respectively.
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Table 6
Structure Property Difference of Novel Ligands in Comparison With CAB02-108/A-412997 on D2 Receptor

92
Novel ligand activity (Inactive: Inactive activity; PA: Partial Agonist; G: G-Protein; β: Beta-Arrestin; W: Weak; Anta:
Antagonism)
2
Docking pose comparison (Flip: Rotated position of the novel ligand in comparison with its parent ligand, showing if the
novel ligands have the same or different orientation as that of the parent ligand; Red: Single ring: Blue: Two ring.
3
Structural differences of receptors are compared by shift in helices and extra- and intracellular loop RMSF activity(TM:
Transmembrane; ICL: Intracellular loop; ECL: Extracellular Loop)
4
Five dihedral angles (τ1 to τ5) of the novel ligand were compared; (++): significant difference; (+): moderate difference; (-) no
difference
1

Table 7
Structure Property Difference of Novel Ligands in Comparison With CAB02-108/A-412997 on D3 Receptor
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Novel ligand activity (Inactive: Inactive activity; PA: Partial Agonist; G: G-Protein; β: Beta-Arrestin; W: Weak; Anta:
Antagonism)
2
Docking pose comparison (Flip: Rotated position of the novel ligand in comparison with its parent ligand, showing if the
novel ligands have the same or different orientation as that of the parent ligand; Red: Single ring: Blue: Two ring.
3
Structural differences of receptors are compared by shift in helices and extra- and intracellular loop RMSF activity(TM:
Transmembrane; ICL: Intracellular loop; ECL: Extracellular Loop)
4
Five dihedral angles (τ1 to τ5) of the novel ligand were compared; (++): significant difference; (+): moderate difference; (-) no
difference
1

Table 8
Structure Property Difference of Novel Ligands in Comparison With CAB02-108/A-412997 on D4 Receptor
Recepto
r

Ligand
CAB02108/A412997

Activity1

Docking pose2
Fli Two Single
p
ring ring

Receptors 3
Helix
Loops
shift

τ1
Purple

Dihedral Angle4
τ2
τ3
τ4
Yellow

Pink

Green

PA(G, β)

ECL1, ICL2,
+
++
ECL2, ICL3
ECL1, ICL2,
CAB02-017 PA(G, β) no
no
yes
++
++
ECL2
D4
PA(G
ICL1, ECL1,
CAB03-015
yes
no
no
TM1,2,
++
++
++
β)W
ICL2, ECL2
PA(G
TM1,3,4, ECL1, ICL2,
CAB02-011
no
yes
yes
+
++
β)W
5,6
ECL2, ICL3
TM2,3,4, ICL1, ECL1,
CAB02-003
Anta
yes
no
no
++
++
++
5,6
ICL2, ECL2
TM3,4,5, ECL1, ICL2,
CAB02-005
Anta
yes
no partial
++
++
+
6,7
ECL2
1 Novel ligand activity (Inactive: Inactive activity; PA: Partial Agonist; G: G-Protein; β: Beta-Arrestin; W: Weak; Anta:
Antagonism)
2
Docking pose comparison (Flip: Rotated position of the novel ligand in comparison with its parent ligand, showing if the
novel ligands have the same or different orientation as that of the parent ligand; Red: Single ring: Blue: Two ring.
3
Structural differences of receptors are compared by shift in helices and extra- and intracellular loop RMSF activity (TM:
Transmembrane; ICL: Intracellular loop; ECL: Extracellular Loop)
4
Five dihedral angles (τ1 to τ5) of the novel ligand were compared; (++): significant difference; (+): moderate difference; (-) no
difference
CAB02-140

τ5
Blue

PA(G, β)

no

no

yes

TM2,3,4,
5
TM3,4,5,
6

++
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+
++
+
+

3.4.7 Discussion
Our method was able to analyze and uncover key interactions between the set of
compounds against the D2 like receptors. When compared with the parent ligand, A412997, the six derived compounds shared similar features which are essential for protein
binding. For the class I compounds, with the feature of a substitution of the piperidine
ring, was able to bind to all three receptor subtypes, interacting with key residues within
the orthosteric binding pocket. One of the most constant interactions that is observed with
class I compounds is the ASP3.32 across all receptors and a Tryptophan residue on TM7.
The class II compounds did not show any major binding within the D2 or D3 receptor. In
the D4 receptor, they were able to interact with similar residues as the other compounds
but still not interact with residues that could influence a major change in their biological
activity. For the class III drugs, they were able to interact with a wide range of residues
within the D4 receptor within the ECL2 region. This interaction was only seen for this
class of drugs alone.
From the clustering analysis of the complexes, different binding poses of each
compound is compared to the parent compound. Significant movement of TM6 an TM7
is observed for the class I compounds, showing how their interactions could influence a
change in their biological activity compared to the other compounds. This is observed for
all D2-like receptor complexes for the class I compounds.
With the substitution of the piperidine ring to the class I compounds has
significantly increase binding affinity to the D2 and D3 like receptors. The addition parasubstitution on the pyridinyl ring of A-412997 for the class III drugs activates a
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antagonist ability. The design of A-412997, (2-(3',4',5',6'-tetrahydro-2'H-[2,4']
bipyridinyl-1'-yl)-N-m-tolyl-acetamide)¸focusing on hydrogen and aromatic interaction
may lead to development of effective pharmacological candidates to target the Dopamine
D4 receptor and treat neurological conditions.
3.5 Conclusion
In this project, we used molecular modeling techniques to reveal the molecular
interactions and docking poses to identify the correlation with their biological activity of
novel compounds against the D2-like receptors. Our work provided insight about what
structural changes to the parent compound could change its binding efficacy profile. By
simulating the different novel compounds within the binding pocket, we can further
optimize these compounds to design new ligands to promote high agonist affinity and
high subtype selectivity of a compound.
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Appendix A
Dopamine Receptor
Table A1
Residue Contact of Ligands for the D2 Receptor Systems From MD Simulation
Generic
Number

CAB02108/A41299
7

2.57
2.6
2.61
2.64
ECL1

CAB02-140

V91 (7.4%)
L94 (43.6%)
W100
(10.4%)
F110
(59.9%)

3.28
3.29
3.32

D114 (9%)

3.33

V115 (2.5%)

3.36

C118
(85.7%)

3.4
ECL2
5.38
5.39
5.42
5.43
5.46
5.47

I184
(12.4%)
F189
(10.4%)
V190
(47.5%)
S193 (9.4%)

F198
(27.7%)

D114
(197.6%)
V115
(11.9%)
C118
(69.3%)
I122 (6.4%)
I184
(10.4%)
F189 (7.4%)

CAB02-017

CAB03-015

L94 (13.9%)
W100
(33.2%)
F110
(81.2%)
V111
(65.3%)
D114
(188.1%)
V115 (1.5%)
C118
(81.2%)
I184
(26.7%)

V91 (6.9%)
L94 (33.2%)
W100
(16.3%)
F110
(77.2%)
V111 (3.5%)
D114
(203%)
V115
(29.2%)
C118
(27.7%)
I184 (3%)

6.51
6.52
6.55
7.35

W386
(63.4%)
F389
(14.9%)
F390
(47.5%)
H393
(15.4%)

V87 (5.2%)
W90 (4.6%)
V91 (22.7%)
L94 (4.6%)
W100
(44.3%)
F110 (6.7%)

CAB02-005

V91 (2.5%)
L94 (11.4%)
W100
(26.7%)
F110
(36.1%)

D114
(223.7%)
V115 (3.1%)

D114
(121.3%)

C118
(59.9%)

C118
(60.8%)

I184
(43.1%)

I184
(12.9%)

C118
(58.4%)
I122 (5%)
I184 (7.9%)

S197 (4%)
F198
(18.8%)

S194 (1.5%)
S197 (5%)
F198 (5%)

S193
(76.7%)
S194 (5%)
F198
(10.4%)

W386
(80.7%)
F389
(35.6%)
F390
(42.1%)

W386
(81.2%)
F389
(59.4%)
F390
(50.5%)

W386
(74.3%)
F389
(42.6%)
F390 (7.4%)

Y408 (5.5%)

Y408 (2.5%)

Y408
(10.9%)

7.39
7.43

L94 (3%)
W100
(31.7%)
F110
(84.2%)
V111
(41.1%)
D114
(189.1%)
V115 (5.9%)

CAB02-003

V190 (6%)

6.44
6.48

CAB02-011

Y416 (4.5%)
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F198
(67.8%)
F382
(25.7%)
W386
(105.4%)
F389
(38.1%)
F390
(27.7%)

F198
(12.4%)
F382 (5%)
W386
(92.8%)
F389 (2.1%)

W386
(89.1%)
F389 (47%)

F390
(37.1%)

F390
(24.3%)

Y416 (2.1%)

Y416 (47%)

Y408
(34.7%)
T412
(45.5%)

Table A2
Residue Contact of Ligands for the D3 Receptor Systems From MD Simulation
Generic
Number
2.53

CAB02108/A412997

CAB02-140

CAB02-017

CAB03-015

CAB02-011

CAB02-003
V78 (4.5%)

2.57

V82 (5.9%)

2.58

M83 (5.4%)

2.6

W85 (91.6%)

2.61
2.64

CAB02-005

V86 (22.8%)
L89 (8.9%)

L89 (28.2%)

V86 (21.8%)
L89 (13.9%)

L89 (8.4%)

L89 (13.9%)

L89 (40.6%)

ECL1

L89 (19.3%)
W96 (14.4%)

3.28

F106 (89.1%)

F106 (38.6%)

F106 (88.6%)

F106 (92.6%)

F106 (63.9%)

F106 (6.4%)

3.29

V107 (28.2%)

V107 (3%)

V107 (11.8%)

V107 (7.9%)

V107 (28.7%)

V107 (2.5%)

V107 (2.5%)

3.32

D110 (152%)

D110 (97.1%)

D110 (26.3%)

D110
(191.6%)

3.33

D110
(191.1%)
V111 (13.9%)

V111 (53.5%)

V111 (23.8%)

V111 (42.1%)

D110
(124.3%)
V111 (5.4%)

D110
(198.5%)
V111 (18.3%)

3.36

C114 (6.4%)

C114 (10.9%)

ECL2

C114 (37.1%)
V180 (3.5%)

ECL2

C181 (10.4%)

C181 (20.8%)

ECL2
ECL2

I183 (6.4%)

5.38

F188 (6.9%)

I183 (22.8%)

5.39

S182 (96.1%)

S182 (5%)

I183 (22.8%)

I183 (58%)

I183 (11.9%)

I183 (8.9%)

V189 (6.9%)

V189 (3.5%)

V189 (5.4%)

V189 (8.9%)

5.47

F197 (29.7%)

6.48

W342
(49.5%)
F345 (7.4%)

F345 (2.5%)

F345 (77.7%)

F345 (41.6%)

F345 (26.2%)

F346 (92.1%)

F346 (7.9%)

F346 (77.2%)

F346 (54%)

F346 (62.9%)

H349 (5%)

H349 (68.9%)

H349
(106.9%)
V350 (43.1%)

H349 (52.5%)

H349 (39.1%)

Y365 (37.6%)

6.51

F345 (8.9%)

6.52

F346 (77.7%)

6.55

H349 (13.9%)

F345 (38.6%)
H349 (58.4%)

F197 (7.4%)

6.56
6.58
7.32
7.35
7.39
7.43

V350 (17.8%)

N352 (5.5%)
P362 (2.5%)
Y365 (4.5%)

Y365 (45.5%)

Y365 (2.5%)

Y365 (80.1%)

Y365 (74.7%)
T369 (3%)

Y373 (3.5%)

T369 (26.2%)
Y373 (5.9%)

T369 (3%)
Y373 (4.5%)
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Y373 (20.3%)

Y365 (8%)

Table A3
Residue Contact of Ligands for the D4 Receptor Systems From MD Simulation
Generic
Number
2.57
2.6
2.61

CAB02108/A4129
97
V87
(12.4%)
L90 (4.5%)

CAB02-140

F91
(36.6%)

F91
(57.4%)

CAB02-017

CAB03-015

V87
(21.3%)
L90 (15.3%)
F91
(45.5%)

CAB02-003

CAB02-005

V87 (4.5%)

V87
(17.8%)
L90 (15.3%)

V87 (5%)

L90 (21.3%)
F91 (9.4%)

2.64

F91 (6.9%)

F91
(12.9%)

E95 (5%)
W101
(25.7%)

W101
(25.7%)

W101
(21.8%)

W101
(42.6%)

W101
(61.9%)

W101
(59.9%)

L111
(10.4%)
M112
(2.5%)
D115
(185.6%)
V116
(44.1%)

L111
(41.6%)

L111 (5%)

L111
(10.4%)
M112
(3.5%)

L111
(25.7%)
M112
(20.8%)
D115
(190.6%)
V116
(27.2%)

L111 (3.5%)

D115
(224.3%)
V116
(23.3%)

M112
(5.4%)
D115
(189.1%)
V116
(24.8%)
C119
(30.7%)

C185
(10.4%)
R186 (44%)

C185
(11.9%)
R186
(12.9%)
L187
(83.2%)

C185
(42.6%)
R186
(2.5%)
L187
(23.8%)

3.25
3.28
3.29
3.32
3.33
3.36
4.6

D115
(168.4%)
V116
(5.9%)
C119
(8.4%)

M112
(12.9%)
D115
(161.9%)
V116
(10.4%)

C185
(30.2%)
R186 (6%)

ECL2
5.38
5.39
5.42
5.43

L187
(10.9%)

L187
(20.8%)

Y192
(59.9%)
V193 (3%)

L187
(86.7%)

V193
(24.8%)

Y192
(25.7%)
V193 (3%)

V193
(4.5%)

S196
(10.4%)
S197
(6.4%)

6.48
6.51

F410
(6.4%)

6.52
6.55

H414
(14.4%)

F410
(17.3%)
F411 (55%)
H414
(15.8%)

F410
(39.1%)
F411
(54.5%)
H414 (3%)

6.58

H414 (53%)

F410
(34.7%)
F411
(2.5%)
H414
(7.4%)

W407
(8.4%)
F410
(34.7%)
F411
(5.4%)
H414
(16.3%)

Q417
(10.4%)

7.39
7.43

W101
(20.8%)
C108 (4%)

V170
(13.4%)

ECL2
ECL2

L90 (3%)

S94 (3%)

2.65
ECL1

CAB02-011

T434
(22.8%)
Y438
(10.4%)

Y438
(39.1%)

Y438
(42.1%)

Y438
(2.5%)

104

H414
(22.8%)

Figure A1
Comparison of the Crystal Pose (Red) and the Glide XP Docked Pose (Blue) of Crystal
Ligand Risperidone in D2 Receptor (PDB 6CM4)
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Figure A2
Comparison of the Crystal Pose (Red) and the Glide XP Docked Pose (Blue) of Crystal
Ligand Eticlopride in D3 Receptor (PDB 3PBL)
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Figure A3
Comparison of the Crystal Pose (Red) and the Glide XP Docked Pose (Blue) of
Nemonapride in D4 Receptor (PDB 5WIU)
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CAB02- 005

CAB02-003

CAB02-011

CAB03-015

CAB02-017

CAB02-140

CAB02108/A412997

Figure A4

Protein and Ligand RMSD Plots of Novel Ligand With D2
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CAB02- 005

CAB02-003

CAB02-011

CAB03-015

CAB02-017

CAB02-140

CAB02108/A412997

Figure A5

Protein and Ligand RMSD Plots of Novel Ligand With D3
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CAB02- 005

CAB02-003

CAB02-011

CAB03-015

CAB02-017

CAB02-140

CAB02108/A412997

Figure A6

Protein and Ligand RMSD Plots of Novel Ligand With D4
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Figure A7
2D Diagrams and Histogram of CAB02-108 /A-412997 Interaction With D2
6X48

CAB02-108/A412997

3X36

6X52

5X39

Figure A8
2D Diagrams and Histogram of CAB02-140 Interaction With D2
3X28

CAB02-140

2X64

6X51
3X36

3X32

6X52
6X48
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Figure A9

CAB02-017

2D Diagrams and Histogram of CAB02-017 Interaction With D2

3X36
ECL1

6X48
3X28

3X29 3X32 6X52

6X53

Figure A10

CAB03-015

2D Diagrams and Histogram of CAB03-015 Interaction With D2
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Figure A11
2D Diagrams and Histogram of CAB02-011 Interaction With D2
5X47

CAB02-011

3X36

3X28
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3X32

ECL1
ECL2

Figure A12

CAB02-003

2D Diagrams and Histogram of CAB02-003 Interaction With D2
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Figure A13

CAB02- 005

2D Diagrams and Histogram of CAB02-005 Interaction With D2

6X51

3X36
3X28

6X48
7X43

3X32

Figure A14

CAB02-108/A412997

2D Diagrams and Histogram of CAB02-108/A-412997 Interaction With D3

3X28

6X52

3X32
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Figure A15

CAB02-140

2D Diagrams and Histogram of CAB02-140 Interaction With D3

Figure A16

CAB02-017

2D Diagrams and Histogram of CAB02-017 Interaction With D3
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Figure A17

CAB03-015

2D Diagrams and Histogram of CAB03-015 Interaction With D3

3X33

Figure A18

CAB02-011

2D Diagrams and Histogram of CAB02-011 Interaction With D3
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Figure A19
2D Diagrams and Histogram of CAB02-003 Interaction With D3
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CAB02-003
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6X55
3X28

3X32

Figure A20
2D Diagrams and Histogram of CAB02-005 Interaction With D3
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Figure A21

CAB02-108/A412997

2D Diagrams and Histogram of CAB02-108/A-412997 Interaction With D4

5X38
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3X33

Figure A22
2D Diagrams and Histogram of CAB02-140 Interaction With D4
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7X43

3X32

118

Figure A23
2D Diagrams and Histogram of CAB02-017 Interaction With D4

CAB02-017

2X61

7X43

3X36

Figure A24

CAB03-015

2D Diagrams and Histogram of CAB03-015 Interaction With D4

ECL2
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Figure A25
2D Diagrams and Histogram of CAB02-011 Interaction With D4

CAB02-011

6X51

ECL2

3X32

ECL1

Figure A26

CAB02-003

2D Diagrams and Histogram of CAB02-003 Interaction With D4
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Figure A27
2D Diagrams and Histogram of CAB02-005 Interaction With D4
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Figure A28

Secondary Structure Abundance of CAB02-005 on D2

122

CAB02- 005

CAB02-003

CAB02-011

CAB02-017

CAB03-015

CAB02-140

CAB02108/A41299
7

Figure A29

Secondary Structure Abundance of CAB02-005 on D3
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Figure A30

Secondary Structure Abundance of CAB02-005 on D4
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Figure A31
Torsion Angle Distribution of CAB02-108/A-412997 and CAB03-015 With D2R
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Figure A32
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-005 With D2R
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Figure A33
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-140 With D2R
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Figure A34
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-003 With D2R
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Figure A35
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-011 With D2R
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Figure A36
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-017 With D2R
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Figure A37
Torsion Angle Distribution of CAB02-108/A-412997 and CAB03-015 With D3R
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Figure A38
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-005 With D3R
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Figure A39
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-140 With D3R
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Figure A40
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-003 With D3R
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Figure A41
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-011 With D3R
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Figure A42
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-017 With D3R
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Figure A43
Torsion Angle Distribution of CAB02-108/A-412997 and CAB03-015 With D4R
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Figure A44
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-005 With D4R
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Figure A45
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-140 With D4R
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Figure A46
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-003 With D4R
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Figure A47
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-011 With D4R

CAB02-108/A412997

CAB02-011

141

Figure A48
Torsion Angle Distribution of CAB02-108/A-412997 and CAB02-017 With D4R
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Figure A49
Binding Pose Comparison Between D2R CAB02-108/A-412997 and CAB02-017
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Figure A50
Binding Pose Comparison Between D2R CAB02-108/A-412997 and CAB03-015
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Figure A51
Binding Pose Comparison Between D2R CAB02-108/A-412997 and CAB02-011
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Figure A52
Binding Pose Comparison Between D2R CAB02-108/A-412997 and CAB02-003
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Figure A53
Binding Pose Comparison Between D2R CAB02-108/A-412997 and CAB02-005
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Figure A54
Binding Pose Comparison Between D3R CAB02-108/A-412997 and CAB02-017
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Figure A55
Binding Pose Comparison Between D3R CAB02-108/A-412997 and CAB03-015
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Figure A56
Binding Pose Comparison Between D3R CAB02-108/A-412997 and CAB02-011
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Figure A57
Binding Pose Comparison Between D3R CAB02-108/A-412997 and CAB02-003
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Figure A58
Binding Pose Comparison Between D3 CAB02-108/A-412997 and CAB02-005
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Figure A59
Binding Pose Comparison Between D4R CAB02-108/A-412997 and CAB02-140
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Figure A60
Binding Pose Comparison Between D4R CAB02-108/A-412997 and CAB02-017
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Figure A61
Binding Pose Comparison Between D4R CAB02-108/A-412997 and CAB03-015
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Figure A62
Binding Pose Comparison Between D4R CAB02-108/A-412997 and CAB02-003
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Figure A63

CAB02-140

RMSF Pairwise Comparison Between A-412997/CAB02-108 And CAB02-140 on D2
Receptor
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Figure A64

CAB02-017

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-017 On D2
Receptor
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Figure A65

CAB03-015

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB03-015 On D2
Receptor
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Figure A66

CAB02-011

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-011 on D2
Receptor
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Figure A67

CAB02-003

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-003 on D2
Receptor
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Figure A68

CAB02- 005

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-005 on D2
Receptor
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Figure A69

CAB02-140

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-140 on D3
Receptor
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Figure A70

CAB02-017

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-017 on D3
Receptor
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Figure A71

CAB03-015

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB03-015 on D3
Receptor
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Figure A72

CAB02-011

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-011 on D3
Receptor
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Figure A73

CAB02-003

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-003 on D3
Receptor
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Figure A74

CAB02- 005

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-005 on D3
Receptor
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Figure A75

CAB02-140

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-140 on D4
Receptor
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Figure A76

CAB02-017

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-017 on D4
Receptor
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Figure A77

CAB03-015

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-015 on D4
Receptor
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Figure A78

CAB02-011

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-011 on D4
Receptor
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Figure A79

CAB02-003

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-003 on D4
Receptor
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Figure A80

CAB02- 005

RMSF Pairwise Comparison Between A-412997/CAB02-108 and CAB02-005 on D4
Receptor
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